theeve appeal the gynCologlCal cancers charity Gynaecology Cancer Research Fund Annual Report and Accounts for the year ended 31 December 2024 Company Reglstratlon Number: 04370087 Reglstered Charlty Number (England and Wales): 1091708 Reglstered Charlty Number (Scotland): SC042612
Gynaecology Cancer Research FurKI Annual Report Incorporallng a Dlrectors. Report and Accounts for the year endlng 31 December 2024 Contents Legal and Admlnlstratlve Informatlon........................................................................................................... From the Chlef Executlve and Chalr of the Board of Trustees................................................................ Towards 2030 - Fast Foard Preventlon............................ ..................................................................... Goals 2025.....................................................................................................,...,............................................... Objectlves and ActlvStles,...,.,.,.,...,.,.,.,.,.,.,.,.,.............................................................................,.,.........,..,..... Alms and Vlslon.................................,.,..........,.,.,.,.,,.,..,,.,..,...,...,.,.,.,.,....,.......................................................10 Achlevements and Performance..,.,.,.,.,..,.,.,.,........ ........................................................,...,........,.,.,..,,..,....10 Structure, Governance and Management....,.,.,.,.....,.,............,.....,.,.....,...,................................................ 21 Flnanclal Revlew 2024,... . .25 Statement of Trustees, Responslbllltles.......,.,.,.,.....,.,.,.,...,............,............. Independent Audltor's Report to the Trustees of Gynaecology Cancer Research Fund ............... 28 Consolldated Statement of Flnanclal Actlvltles (Incorporatlng an Income and expendlture account) for the year ended 31 December 2024..............,.,.,.................................................................. 33 Consolldated and Charlty Balance Sheet as at 31 December 2024.,.....,........................................... 34 Consolldated Statement of Cash Flows for the year ended 31 December 2024............................. 35 Notes to the Fln8nclal Statements......................................................,.,......,....,.,.,..................................... 36 .26
Gynaecology Cer Research Fund Annual Rewt Incorpor8tlng a Dlwect¢Ms' Report and Att<wnts for the year endlng 31 December 2024 Legal and Admlnlstratlve Informatlon Charlty Name Gynaecology Cancer Research Fund - operatlng as 'The Eve Appeal. Trust• Tamara Box {Appolnted 0110712020) (Chalr of Trustees effectlve 0810212024) Sarah Clark (Appolnted 0411112019) lan Drew IAppolnted 2910912016} Dr Chrlstlne Ekechl {Appolnted 2611012020) Prof lan Jacobs (Appolnted 2910512022) Sarah Morrls {Appolnted 1911212019) Marlon O'Hara {Appolnted 2711012021) Cathy Plttham-wlley IAppolnted 0411112019) Prof Adam Rosenthal {Appolnted 2611012020) Sally Balley {Appolnted 1811012023) Dee Brecker {Appolnted 1811012023) Emma Dean {Appolnted 1811012023) Chlef Executlve Athena Lamnlsos R•ght•r•d Ch•rlty Numb•r (England and W•l••): 1091708 Reght•red Charlty Numb•r (Scotlandl: SC042612 Reghtered Company Number. 04370087 Prlnclpal Offlce of Charlty and Reglster•d Offlce The Eve Appeal. 10-18 Unlon Street. London. SE11SZ Audltor Moore Klngston Smlth LLP. 6th Floor, 9 Appold StreeL London. EC2A 2AP Bankers CAF Bank Llmlted, 25 Klngs Hlll Avenue, Klngs Hlll, West Malllng, Kent, ME19 4JQ Unlty Trust Bank ple, PO Box 7193, Planetary R08d, Wlllenhall, WV19DG Sollcltors Bates Wells. 10 Queen Street Place. London. EC4R 1BE Reed Smfth, Broadgate Tower. 20 Prlmrose St. London EC2A 2RS
Gynaecology Cancer Research FurKI Annual Rewt IncorporatlNJ a Dlrectors. Rewt and Accounts for the year endlng 31 December 2024 From the Chlef Executlve and Chalr of the Board of Trustees We remain flrmly focused on preventlon and earty dlagnosis and seelng a world where all gynaecological cancers are prevented or detected at an early stage. Women make up 51% of the population but thelr heafth has been under prlorltlsed: Investment In preventlon has been neglected and dlagnosis still comes far too late. Eve have malntslned our ambftlon to accelerate progress on earty dlagnosls and preventlon by Investlng In medlcal research and educatlon. Thls Is reflected In the fundlng of our second research fellow who wlll focus hls programme on looking at new markers for ovarlan cancer. Thls Is a dlsease where late diagnosSs has remained stubborn. We are really exclted to award thls fundlng at a new centre, the world class Edinburgh University and to fund this programme In partnershlp wlth North West Cancer Research. The power of collaboratlon to double the Investment In our gynaecologlcal fellowshlps programme Is somethlng we are very proud of. We were dellghted to recelve support from the Medlcal Research Councll for our fellowshlps programme durlng the year. Investlng In the next generatlon of researchers Is a shared ambltlon. Durlng 2024. we worked wlth the whole Eve communlty to revlew our mlsslon, vlslon and values. We dld thls to provlde a strong foundatlon to our new strategy, whlch wlll see us reach goals across research, awareness and publlc educatlon by 2030. We have stepped up our pollcy work,. to evldence how those affected by gynae cancers are often falled. to provlde expert Inslght Into what need5 to change and to outllne how change can happen. We are contrlbutlng Inslghts to a range of natlonal and Internatlonal forums and pollcy programmes Includlng h05tlng an event for MSPS In the Scottish Parllament In November. Th15 work has largely focused on cervlcal cancer ellmlnatlon whlch Is an ambltlous natlonal goal set for England. We're very proud to see our work recognlsed and were honoured to recelve the award for Internatlonal advocacy from the Internatlonal Gynaecologlcal Cancer Soclety In 2024. The ambltlon Is always to change and Influence cllnlcal practlce and we're dellghted to see the launch of the NHS Jewlsh BRCA testlng programme after Eve's many years of Investlng In and provlng the Ilfe-savlng and economlc case for thls programme. Whlle Important progress has been made across gynaecologlcal cancer awareness, our work and the contacts to our Ask Eve nurse Informatlon seNlce tell us that they are stlll belng overlooked and that we need to contlnue our efforts on drlvlng forward awareness on the slgns, symptoms and rlsk factors of all five dlsease5. We know that fundlng ploneerlng research can be transformatlonal. It can create a step change and enable us to have hope for the future. Investlng In research that wlll uncover new ways of dlagnoslng ovarlan cancer, Identlfylng how to dlfferentlate those affected by benlgn womb condltlons so that cancer can be ruled out at the earllest stage and progressing our work In vulval cancer. have been highlights durlng the year. We have additionally supported wlder research Initlatfves Including the first national womb cancer audlt and a programme to look at specific barrlers which those affected by physlcal disability face when accesslng cervlcal screenlng. We have expanded our Ask Eve seTvlce so that the support, whlch is mlsslng for too many. Is avallable. Our unique nurse-led informatlon Ilne has supported a 1000% Increase In contacts about ceNlcal cancer, cervical screening and HPV. Thls resulted from the closure of a cervical cancer charity and both reflects the fragllity In the charlty sector and the huge need for informatlon and support. We are looklng at Innovatlve ways to further expand thls servlce and are dellghted to have secured fundlng from a collaboration of two corporate partners, to develop a
Gynaecology Cancer Research Fund Annuol Report Incorporallng a Dlrectors. Report and Accounts for the year endlng 31 December 2024 dlgital solutlon to help provide expert information to even more people by the end of 2025. Desplte the challeng5ng economlc climate, we met our income targets and are grateful to our partners. donors and all those in our community who have supported us wlth glfts in kind and generous donatlons. The Eve team of expert, committed and ambltlous staff. trustees. volunteers and advocate5 have made all our success posslble. These are unprecedented tlmes, but a shlft to preventlon in healthcare won't wait or happen, without all of us drlvlng It forward. Our ambition and resolve remains: to Invest In research, educate people about gynaecological cancers, offer expert informatlon, and Influence policy nationally and Intern8tionally. And it remains time crltlcal. ,Now Is the tlme to fast forward preventlon. Our 2025-2030 strategy wlll bulld on our momentum and impacL It will harness our partnershlps and collaboratlons. our new dlgltal opportunities and our growlng reach to ensure that no one Is left behlnd. Our focus on outreach. addressing health Inequalltles and Includlng 811 those affected by gynaecologlcal cancers across our programmes Is at the heart of our work. Eve have achleved so much, but there's stlll so much more to do. Together, wlth our commltted and generous communlty- and wlth those affected by the flve gynaecological cancers as our touchstone- we are confldent that we can move towards a world where all gynaecologlcal cancers are prevented or detected at an earty stsge. Athena Lamnlsos, Chlef Executlve Offlcer Tamara Box, Chalr of the Board of Trustees
Gynaecology Cancer Research Fund Annual Report Incow8tlng 8 Dlrectors. Rewt and Accounts for the year endlng 31 December 2024 Towards 2030 - Fast Forward Preventlon The Eve Appeal is the leading gynaecological cancer charty. Our alm Is to prevent gynae cancers from developlng In the first place, but If they do develop. we want to make sure they're detected early so more people survive their dlagnosis. To make our goals a reallty, we fund research In four key areas: uncoverlng the causes of gynae cancers, predlcting a person's rlsk of developlng them, Identlfylng how people can reduce thelr rlsk, and Improving thelr detection and diagnosls. We educate people about gynae health. from knowlng thelr anatomy. what's normal and what's noL and when to seek help. We alm to Increase awareness of the slgns and symptoms of gynae cancers and what people should do If they spot anythlng they're worrled about. Through our Ask Eve nurse *rvlce, we answer people's questlons about thelr gynae health, gynae cancers and provlde vltal reassurance. Thls free, confldentlal and expert support Is avallable over the phone, vla emall and through our webslte. Dev•loplng our n•w strat•gy- th• n•xt Ilv• y•ar•, the Journey to 2030 We w511 focus on slx core strateglc areas durlng 2025: 1. Revlewlng our organlsatlonal strategy and creatlng a roadmap to take u5 to 2030. 2. Fundlng a new 3 year research fellowshlp and awardlng research fundlng to the rare gynaecologlcal cancers. 3. 8ulldlng our fundralslng partnershlps programme to contlnue to grow the Income that we have seen In thls area. 4. Expandlng our Ask Eve and outreach seNlces so that we can address Identlfled health Inequalltles around gynaecologlcal health. 5. Internatlonallslng our research and pollcy work so that we can share Eve's expertlse and explore future fundlng opportunltles. 6. Investlng In our team to ensure reslllence and su5talnablllty and augmentlng resources wlth dlgltal solutlons along51de tralnlng and Investment. Goals 2025 Invest In Innovatlon and dlscovery We wlll unlock new and better ways to understand gynae cancer, through seed-funding Innovatlon and moonshot research programmes. We wlll explore new avenues to fund our researchers, Includlng commerclal opportunltles that arlse from research. We wlll streamline the way we work and engage to help achleve our mlsslon. A speclfic focus wlll be In supportlng a womb cancer detectlon test whlch has resulted from Eve funded research. belng evaluated and movlng Into malnstream healthcare. Engage and translate We will accelerate our research flndlngs Into cllnlcal practlce, by sharlng Impact wlth the broadest range of policy. public, academic. lived-experience and cllnlcal stakeholders. We will seek out those who need access to our health Informatlon and ensure ft is shared Sn a way that Is accesslble and relevant to them. We wlll be Investlng In our 'Eve Voices, network of clinical. research and expert by Ilved experlence durlng the year.
Gynaecol¢)gy C8ncer Research Fund Annual Report IncOrp811n9 a Dlrectors. Report and Accourbts for the yev endlng 31 December 2024 Drlve support for our vlslon through collaboratlon We wlll work across dlsciplines. across boundarles and connect In meanlngful ways wlth all of our new and exlstlng stakeholders. wlth the alm of ralslng the funds necessary to achleve our mlsslon. Buildlng our research co-fundlng across the charlty sector and wlth other partners wlll be our focus. Influence the new NHS 10 Year Plan Maklng preventlon and early detectlon central to dellvery and ensure that we can support the development and Implementatlon of dellvery so that It reaches all parts of the communlty. PrIorltl & Plans The Eve Appeal team have made excellent progress agalnst the actlon plans In the 3-year strategy. The following actions have been Identlfled to ensure we meet the ambltlous targets set two years ago: R•s•arch and Advocacy Contlnu• advo¢atlng for gyna•cologll ¢an¢•r re•ear¢h fundlng by worklng wlth pollcymakers. funders and key stakeholders to hlghllght the need for more research on rlsk predlctlon and early detection of the five gynae cancers. Contlnue to develop partn•r•hlp• wlth r•••4h ¢h•rftl to fund collaboratlve progr8ms and campalgns. luu• •n opm 11 for a thlrd JoIntsfund f•llow•hlp In 2024 acr055 all flve gynae cancers, to contlnue our support of early career researchers. Launch a new Small Grants fundlng call to klck-start Innovatlon and bulld connectlons wlth the broader research communlty. Strengthen Int•matlonal rM•ar¢h n•twork• by Increaslng stakeholder engagement and partlclpatlon wlth European and InternatSonal counterparts. Dev•lop connectlons wlth research Instltutlon• and unlversltl•s In th• UK to bulld our proflle and network wlthln the research communlty and bulld a plpellne of future appllcants. Ask Eve Prlorltles Support d•v•lopment of t•chnlul Int•vv•ntlons to address Increaslng seNlce demands. Revlew and updat• A•k Eve •valuatlon •y•t•m• to enhance Impact measurement and reportlng. Pllot th• Introductlon of experlen¢ed volunteer• to •upport th• Mrvlc• by developlng the systems and processes wlthln Ask Eve and the wlder charlty to traln. support and recognlse volunteer ¢ontrlbutlons.
Gyn8ecol¢)gy Cancer Research Fw Annual Report Incorporaung a Dlrectors. Report and Accounts ts the year endlng 31 December 2024 Outreach & Awareness Prlorltles Embed the brand r•fr•8h by ensuring staff and stakeholders conslstently use updated branding across all platforms and use the refresh as an opportunity to engage new audiences. Health Informatlon development. Continue to ievlew exlstlng material and develop new health infoimation for audiences with the greatest barrlers to access. Contlnu• to d•v•lop Eve Vok•s. Complete the consuttatlon process and Implement practlcal steps for engaglng and supportlng volunteers and advocates. Contlnue t• flll th• gap left by th• ¢losur• of Jo's Cervkal Cancer Tt. Develop a 2025 plan to priorltise content updates and specifically to ensure both publlc and healthcare audiences have access to comprehenslve information on cervical cancer. screenlng and HPV. Strat•gk Plannlng Develop a new adaptlve strategy In consuftatlon wlth key stakeholders to address prlorSty areas and ensure Eve Is meetlng Its ambltlon, goals and charltable objectlves. Gov•manc• and Peopl• Con•olldat• th• gov•rnanc• •tructum wlthln the Board of Trustees and support contlnued functlonlng of the Flnance and Audlt Committee, Research Cornmlttee and the creatlon of a new Development Board. Contlnue •mb•ddlng tho •qulty. dlv•r•lty and Inclu•lon workplan across all our actlvlty, focuslng on cTrproductlon and workSng wfth patlents and other groups to ensure that everythlng we produce meets the needs of the communltles who would beneflt from our Snformatlon and servlces, Compl•t• the r•vlslon of all workplac• polkl•s and procedures (from cyber securlty to enhanced parental leave) and roll out tralnlng to all staff. Thls wlll ensure the team Is supported and can operate effectlvely and ensure that the charlty Is operatSng to best practlce In all areas. Fundraldng Contlnue wlth our test-learn-optlml8e approach acr055 our fundralslng programme to ensure we contlnue to Improve our overall fundralslng programme. Contlnue ¢)ur strat•glc focus on growlng our Income from buslnesses and speclflc81ty multl-year partnershlps to better dlverslfy our Income sources. Launch our nwi D•v•lopm•nt Commltt•• wlth a focus on ralslng the restrlcted Income we need to fund our research programmes. Undertak• a complet• r•vl•w of our fundrahlng programmè and resources to ensure they are frt for the future.
Gyn8ecology Cancer Research Fund Annual Report Incorporatlng a Dlrectors. Report Accounts for Ihe yew endlng 31 December 2024 Flnanclal Management Given the size of the charity. we have a lean financial management but slgnlficantty efficlent structure. Key highlights of financial management structure Includes: Produclng monthty management accourrts wlth sumrnary explanatlon to the Senior Management Team. Annual revlew of all flnance processes. pollcles and procedures as set out by the Charlty Commlsslon. Quarterly Flnanclal reportlng to the Board of Trustees and Flnance and Audlt Commlttee for regular monltorlng of financlal matters. Annual budget and reforecast wlth cashflow reportlng to the Board of Trustees and Flnance & Audit Committee. Dual 8Uthorlsatlon system of banklng transactlons. Annual statutory audlt carrled out by a flrm of chartered accountants. Reportlng to ststutory bodles Includlng Charltles Commlsslons and Companles House, Revlewlng and restructuflng our Investment pollcy to Increase returns. Worklng closely wlth our Treasurer and Trustees to revlew our rlsk management and mltlgatlon processes. Objectlves and Actlvltles Introductlon Orlglnally founded as the Gynaecology Cancer Research Fund In 1984 by Professor lan Jacobs, The Eve Appeal was estsbllshed In 2002 to ralse awareness and funds Into the research of the flve gynaecologlcal cancers: womb. ovarlan, cervlcal. vulval and vaglnal. Every day In the UK, 60 women and people wlth gynae organs are dlagnosed wlth a gynaecologlcal cancer and 21 wlll dle. Improvlng these grlm statlstlcs wlll take targeted Investment In preventatlve research, but only 5% of UK cancer research fundlng goes on preventlon and a tlny percentage of the total on the gynaecologlc81 cancers. One In three people can't name a gynae cancer and one In four have felt not Ilstened to In a gynae heafth appolntment. The Eve Appeal was set up to save Ilves by fundlng ground-breaklng research; slnce 2015 we've awarded over £3m to research focused on developlng new screenlng. rlsk predlctlon and early detectlon methods. The research we fund Is ambltlous and challenglng. whlle our razor-sharp focus means our fundlng leverages further fundlng from other sources. Alongslde research. we also ralse vltal awareness of slgns and symptoms. break down taboos and stlgma and offer a free. nurse-led information seNlce, where anyone can ask anything. The case for Investlng In gynaecologlcal cancer research has never been more needed. As a research charlty. we are proud to have been able to contlnue our research Impact by Investlng new funds thls year and not pauslng or reduclng any prevlously awarded research funds. Gynaecology Cancer Research Fund. tradlng as The Eve Appeal. Is a company Ilmited by guarantee and a reglstered charity. In Its memorandum and articles of association {last updated 2 February 2022). the Charlty's objects are outllned as follows:
Gynaecology Cancer Research Fund Annual Report IntoOratIng a Dlrectors. Report and Accounts for the year endlng 31 December 2024 To advance and fund research Into gynaecologlcal cancers and dlssemlnate the results of such research: To advance public education and thereby ralse the proflle and awareness of gynaecologlcal cancers, their signs and symptoms and rlsk factors (including BRCA and Inherlted rlsks): To relleve the needs of women affected by the gynaecologlcal cancers and Inherlted rlsk factors (Includlng genetic mutatlons) by provldlng Informatlon and support servlces for these women, thelr famllles, frlends and health and soclal care professlonals. Alms and Vlslon There are fve gynae cancers. whlch are womb, ovarlan, ceNlcal, vulval and vaglnal cancer. The world-leadlng research that we fund Is ambitlous and challenglng but our vSslon Is slmple: A world where all gynaecologlcal cancers are prevented or detected at an earller stage. Publlc Benefit Statement In reportlng on the objectives and achlevements of the Charlty, the Trustees have glven due regard to the Charlty Commlsslon guldance on publlc benefit under the Charltles Act 2011. The Gynaecology Cancer Research Fund constltutes a publlc beneflt entlty as deflned by FRS102. Achlevements and Performance R•ah In the flnal year of our three-year strategy, we have made slgnlflcant progress on our objectlves set In 2023: Establlsh The Eve Appeal Fellowshlp Programme Support early c8reer researchers Fund research across all five gynaecologlcal cancers Support our herltage core programmes Strengthen and support the Research Advlsory Commlttee Capture and share Impact of research actlvlty across the organlsatlon Develop patlent engagement wlth research. Establlsh The Eve Appeal FellohIp Programme - •upp¢)rtlng earfy career re•earch•r• and engaglng the pfitlent voke In revlew Wlth Ilmtted fundlng, and uncertaln pathways. the challenges for researchers worklng In gynaecologlcal cancer are numerous. In 2023, our Board of Trustees agreed to contlnue our legacy of Investlng In the next generatlon of gynaecological cancer research stsrs through a fellowshlp scheme. The alm was to attrad and retsin researchers In the fleld, by providlng substsntlal flnanclal asslstanee, resources, network, support and opportunltles. After the successful launch of the fellowshlp programme In 2023 and the development of a solld partnershlp wlth North West Cancer Research, our Inaugural fellow. Dr Kelechl Njoku from the Universlty of Manchester, was chosen. Dr Njoku and his team are working to develop a gentler test to diagnose womb cancer using proteins in the vaglnal fluld. 10
Gynaecology Cancer Research Fund Annual Report IncorpalIng a Dlrectors. Report and Acc<wnts for the yew endlng 31 December 2024 In 2024. wlth funds avallable In a restrlcted fundlng pot for ovarlan cancer. our second fellowship call was launched. We recelved several strong appllcatlons from across the Ulc We solldlfied our revlew processes and Incorporated the volce of the lived-experience communlty. to ensure that thelr vlews on research prlorltles were heard. Drawing on the support of the volunteers In Ovarian Cancer Action's Research Network, we engaged wfth 16 women wlth Ilved experlence to provide written feedback and partlcipate In a focus group and dlscusslon on the appllcants and their projects. Their input was hugely valued, Insightful and Important. Feedback from thls panel was shared wlth all applicants, to inform any future appllcatlons they make. After rlgorous external peer revlew, lfved experlence revlew and scrutlny from our Research Advlsory Committee. Dr Nell Ryan from the Unlverslty of Edinburgh was awarded our second fellowshlp. Dr Ryan Is worklng to develop a blood test to detect ovarlan cancer at fts earllest stages. Fund r•s•arch across all lfv• gyna•cologkal canc•r• - actlve grants 2024 The Eve Appeal Is the only UK charSty funding research across all flve gynaecologlcal cancers, Rar• Gyna• Canc•r R•••arch Fund Research on rare gynaecologlcal cancers Is Ilmlted, leadlng to later dlagnoses and fewer treatment optlon5. For patSents wSth even rarer subtypes, there may be no actSve research at all. Recognlslng thls need, The Eve Appeal, supported by dedlcated donors Impacted by these cancers. now supports four ploneerlng projects to deepen understsndlng and Improve outcomes for those affected. AdvancH In Earfy D•t•ctlon for Vulval Cancer and Prfrcancerou• Condftlon• Professor Marla Kyrglou's team at Imperlal College Londonls ploneerlng a new approach to dlagnoslng and treatlng vulval cancer. Vulval cancer Is a rare form of cancer affectlng around 1,400 women In the UK each year. Dlagnoslng and treatlng vulval cancer Is challenglng as symptoms can mlmlc other condltlons and surgery often requlres multlple procedures whlch causes slgnlflcant physlcal and psychologlcal Impacts. Marla's team Is developlng an Innovatove dlagnostlc technology called Laser-Asslsted Rapld Evaporatlve lonlsatlon Mass Spectrometry {Laser-REIMS). Thls technology uses a laser to sample tlssue, generatlng a vapor that can Instantly Identlfy whether the tlssue Is healthy or precancerouslcancerous. Inltlal studles uslng Laser-REIMS In other gynaecologlcal cancers. Ilke ovarlan and cervlcal cancer. show promlslng results and Marla's team aim to extend thls technology to vulval cancer. By Identlfylng affected areas In real tlme. thls approach could reduce the need for repeat surgerles. mlnlmlse the removal of healthy tlssue and Improve outcomes for patlents by ensurlng that cancerous tlssues are completely removed In a slngle surgery. Thelr work has already recelved recognltlon. wlth Dr. Marla Paraskevaldl, a lead researcher, presentlng findlngs at major Internatlonal conferences and wlnnlng multiple awards. New R•s•arch Focused on Understandlng and Detectlng Muelnou8 Ovarlan Can¢•r Mucinous ovarian cancer is a rare and hard-to-treat type of ovarian cancer. accountlng for only 2- 3% of ovarian cancer cases. Professor Sudha Sundar and her team at the Universty of Birmingham are investigating five speclfic hormone markers they Identlfled as belng Ilnked to mucinous ovarSan cancer. They wlll use "3D organolds" minl tumour repllcas grown from actual cancer cells to help mimic real tumour behaviour In the lab. 11
Gynaecology Cancer Research Fund Annual Report Incorporallng a Dlrectors, Report and Accounts for the year endlng 31 December 2024 Thls project Is co-funded by the Blrmlngham Women's Global Health Research Programme. It has also galned matched funding. allowlng the team to expand their research collaboratlons nationally and Internatlonally. The team has worked wlth diverse communitles to make thls research accessible. translatlng informatlon Into multlple languages and engaging wSth patlents directly. Through thls Innovative approach, Sudha and her team are working to uncover new Inslghts Into muclnous ovarlan cancer that could not only Improve detection but also explore posslble treatment optlons and make a real difference for women wlth thls dlsease. Re8•arch on Vulval Canc•r Alms to Identlfy Rlsk Factors for Women wlth Lkhen Sclerosu• Many women wlth vulval cancer also have a noncancerous skln condltlon called lichen sclerosus, whlch causes perslstent Inflammatlon and affects the vulva and anal area. Although only a small percentage (5%) of those wlth Ilchen sclerosus go on to develop vulval cancer. the reasons why some do and some don't remaln unknown. Dr Jason Yap at the Unlverslty of Blrmlngham wlll examlne whether speclflc genetlc changes, or mutatlons. In cells could explaln why vulval cancer develops In some women wlth Ilchen sclerosus. HIS team wlll analyse blopsles from women wlth Ilchen sclerosus and those wlth both Ilchen sclerosus and vulv81 cancer to look for these changes. By Identlfylng any patterns, Jason hopes to uncover who may be at hlgher rlsk. allowlng doctors to better monltor and support those Indlvldu8ls. For those at low rlsk. It could mean less frequent check-ups, whlch could ease anxlety and Improve thelr quallty of Ilfe. Now R•••ar¢h to Improv• DIagnlS Of Ut•rln• Sarcomas Uterlne sarcomas are a rare and aggresslve type of cancer that affects the womb. They account for around 3 In every 100 uterlne cancers and are challenglng to dlagnose accurately because they share many symptoms and Imaglng features wlth common. non-cancefOUS growihs called flbrolds. Currently. only 8bout one-thlrd of uterlne sarcomas can be detected through standard blopsles of the womb Ilnlng. Thls can lead to delayed dlagnosls. whlch may worsen outcomes for affected women. Dr. Esther Moss and her team at the Unlverslty of Lelcester are developlng a blood test to help Identlfy uterlne sarcomas early and rellably. Thls test wlll be based on clrculatlng tumour DNA (ctDNA) - tlny fragments of DNA shed by cancer cells Snto the bloodstream. Thls project Is partlcularly Important for Black women. who are at hlgher rlsk of both flbrolds and uterlne sarcomas. Early and accurate dlagnosls wlll allow for more tsllored and safer treatment, Improvlng outcomes for women wlth thls rare type of cancer. n• •areomM ar• r•re canc•rs can •po Impacts on pathnts and thelr lamlll••. It l• fanlasllc that Th• Ev• App•*l Is •upportlng thls prol•ct whlch alms to m•k• a r•al.world Imp•¢t on v4om•n wh arn su•p•ct•d of havln9. or dlagno••d wlth. • uterln• sarcoma. - Dr E•th•r Mo en v•s 66 Vufval Cancer Research Fund New Hope In Vulval Cancer Re••arch Through Innovatlv• Earty D•tectlon Approaehes Dr. Jackle McDermott and her team at Imperlal College London are working to develop our understsndlng of vulval cancer. a condltlon that affects over 1.400 women In the UK annually. Worklng with the advocacy group Vlslble Vulvas. Jackle's research is exploring the genetic changes that occur In two types of pre<ancerous leslons - those linked to HPV Infectlon and those associated wlth non-HPV Inflammatory conditions. Ilke Ilchen sclerosus. 12
Gynaecology Cer Research Fund Annual Report Incorporallng a Dlrectors. Report and Accounts for the year endlng 31 December 2024 The research team uses a powerful technlque called spatlal transcrlptom5cs. whlch allows them to map gene activity withln sections of vulval tlssue. Thls approach provldes a detailed view of how healthy skin can progress to pr&cancerous or cancerous states. By visualising this process at the genetic level, they hope to uncover early warnlng markers that could lead to earlier diagnoses. more targeted treatments. and potentially reduce the need for disfiguring surgeries. Small C•ll Ovarlan Canur R•••ar¢h Fund Research Advanc•s for Rare Ovarfan Can¢•r SCCOHT. Brfnglng N•w Hop• to Young Women Wlth support from The Eve Appeal. Dr Wllliam Foulkes and hls team at MCGIII Unlverslty. Canada. have been worklng to understand and ultlmately treat Small Cell Carclnoma of the Ovary, Hypercalcemlc Type (SCCOHT)-a rare but aggresslve ov8rlan cancer that affects young women and adolescents. Drlven by varlatlons In the SMARCA4 gene, SCCOHT Is challenglng to dlagnose and treat. Many of these gene varlatlons, known as varlants of uncert8ln slgnlftcance. create dlfflcult declslons for patlents and doctors. To address these challenges, Wlll and hls team have created the SCCOHT & SMARCA4 Reglstry and Blobank-a global resource where data and blologlcal samples are gathered to help researchers worldwlde understand SCCOHT better. The reglstry has become an essentlal hub for sclentlsts. doctors. and advocates worklng together to Increase awareness, Improve dlagnosls and develop treatment optlons for thls dlsease. Donor support through The Eve Appeal has been essentlal. enabllng thls Ilfe-changlng research to move forward and glvlng hope to young women wlth SCCOHT. Small Re••arch fjr•nts S¢h•m• Supportlng N•w Horlzon• In ¢an¢•r D•t•rtlon f•r Wom•n wfth Lyn¢h Syndrom• The Eve Appeal has funded crltlcal research at UCLH to explore earty detectlon methods for womb cancer In women wlth Lynch syndrome. Women wlth Lynch syndrome are at Increased rlsk for multlple cancers, Includlng womb cancer, and face tough decSslons about rlsk-reduclng surgery. For those who choose to delay or decllne surgery, havlng a rellable survelll8nce optlon Is cruclal-yet exlstlng guldellnes don't currently recommend any standard gynaecologlcal screenlng, Leavlng these women wlth Ilmlted alternatlves. Thls project alms to change that by Investlgatlng whether speclflc changes In DNA rep8lr protelns wlthln the womb Ilnlng can Indlcate the early onset of cancer In women wlth Lynch Syndrome. Thls effort could ultlmately gulde more personallsed surglcal tlmlng, glvlng women the optlon to delay surgery untll It's genulnely needed. The fundlng has been a catalyst, helplng the team secure addltlonal resources to expand the study wlth DNA methylation anatyses-a promising avenue for future survelllance testlng. Iner•aslng Awarén•ss ol Gynaecologlcal Cancer In Young Women In Unlv•rslty The key to detectlng cancer earty Is Ilfelong awareness, where people have an understandlng of the signs and symptoms, are looklng OLrt for them and any changes to thelr body and golng to medical professionals to get checked. Dr. Trlsh Holsch and her team at Leeds Beckett Unlverslty have developed an Innovatlve educatlonal programme almed at Increaslng awareness of gynaecological cancers among unlverslty students. Partlclpants reported galnlng a greater understandlng of gynaecological cancers and increased confldence In recognlslng and addresslng symptoms. The study also found that partlcipants felt more open discussing gynaecological health, whlch helped reduce stigma. Thls Inltial success suggests that the programme could be expanded to universities across the UK helplng more young people become proactlve about thelr health. 13
Gynaecology CarKer Researth Fund AMU81 Report Incwratlng 8 Dlreclors. Rewt and Accounts for the yw endlng 31 December 2024 Th• Endom•trlal Canc•r Audlt The Eve Appeal are working together wlth the Brltlsh Gynaecologlcal Cancer Soclety. the British Associatlon f G naecolo ical Pa holo ists (BGAP) and Peaches Womb Cancer Trust to establish the Endometrlal Cancer Audit. Focused on womb cancer, the audit has a few aims: to raise the profile of the disease, to assess regional variation In management and outcome and to promote the call for a fulty commlssloned publlcly funded natlonal audit. The pilot was launched at the BGCS annual conference In August 2024. wlth Helen Hyndman MBE from The Eve Appeal on the steerlng commlttee. Support our H•rltag• Cor• Programmeg Followlng several years of strateglc support, a flnal set of research grants are belng awarded to Professor Martln Wldschwendter's team at Unlverslty College London to ensure the continued momentum of hls Eve-SUPPOrted portfollo of research as he works to secure long-term funding from other sources. Professor Wldschwendter's team has been generatlng new data on eplgenetlc tests used In the early dlagnosls of breast and gynaecologlcal cancers. Thelr focus has been on early detectlon of womb cancer wlth the slmple PCR-based WID-qEC test. The team dellvered a study - the EPI- SURE study- evaluatlng the test In 8 real-llfe settlng at UCLH wlthln Professor Davor Jurkovlc's gynaecologlcal rapld access cllnlc. Results of the study were publlshed In the Lancet Oncology In November 2023: the WID-qEC outperformed Imaglng at rullng out womb cancer and could save nearly 90% of perl- and post-menopausal women wlth abnormal bleedlng from needlng Invaslve surglcal blopsles. Wlth The Eve Appeal's support, the team examlned whether the WID-qEC test could be used to Identlfy womb cancer durlng routlne survelllance of women wlth a genetlc predlsposltlon for the dlsease (Lynch syndrome). They also examlned the performance of the test wlth Black women In the UK. After many years of support, It Is excltlng to see that the team's efforts move closer to belng accesslble for all women and people wtth gynae organs In the UK on the NHS. Strengthen and Support the Re•earch Advlsory Commlttee The Research Advisory Commlttee Is an external group of research experts and people wlth Ilved experlence who advise the Board of Trustees and the Senlor Management Team on research matters at the charlty, Includlng the followlng responslbllltles: To provlde expert sclentlflc advlce and Intelllgence to The Eve Appeal. To asslst the Head of Programmes, Research Commlttee and Board of Trustee5 wlth strategic planning and prlorltlsatlon. In Ilght of current knowledge and activity in gynaecological cancer research and make recommendations on the allocatlon of avallable research funds. To provlde an external peer revlew functlon to assess research project proposals and Identlfy and recommend the most approprlate projects for financlal support. To assess ongolng research programmes and report flndlngs to the Board of Trustees, advising on any necessary course of action or additional informatlon requlrements. To review evaluation of completed projects to assess Impact. To ensure compllance wlth Assoclatlon of Medlcal Research Charltles guldance on peer revlew. 14
Gynaecology Canr Researth Fund Amual Rep Incorporatlng a Dlrectors. Rewt and Accounts for the year endlng 31 December 2024 In 2023. a new Chalr. Professor Emma Crosble was appolnted. and she stsrted In posltlon In January 2024. Three addltlonal new members Jolned In early 2024. Professor Anne Lanceley. Dr Garth Funston and Professor Raji Ganesan. The Research Committee - whlch Is a Board sub-commlttee - contlnues to work effectlvely and fulflls a number of Important functlons at The Eve Appeal. Thls Includes research strategy and plannlng; provldlng assurance about the peer and Research Advlsory CommSttee revlew process (includlng handllng any challenges or confllcts of Interest that arlse): scrutlny of research project budgets. overseelng research financlal commltments and managing rlsk and associated mitlgatlons arlslng from research actlvlty. Captur• and Shar• Impact ol R•Jeareh Actlvlty Acros• the Oryanlmllon The Eve Appeal produced Its first Research Update report In 2024, whlch shared detalls on all current funded proJe¢t5 and the Impact our legacy projects have had, This document has been Invaluable not only for donors and supporter5 to understand actlve projects and what they hope to achleve, but for staff and trustees to understand The Eve Appeal's Journey over the last 23 years and the Impact of the research funded durlng thls tlme, More work on legacy project Impact wlll be undertaken In 2025. Ask - Nur•frL•d Informatlon Sorvlc• Our Ask Eve servlce contlnues to be a vltal servlce for anyone concerned about thelr gynaecologlcal health. Ask Eve Is essentlal In promotlng early dlagnosls, encouraglng pieventatlve actlon for those at rlsk and supportlng those dlagnosed and thelr loved one5 at all stages of the pathway and beyond. We also provlde Informatlon to health care professlona15 who have questlons about patlents under thelr care, enabllng them to offer correct, evldence-based Informatlon and guldance. The ongolng NHS pressures and the sad, unexpected closure of Jo's Cetvlcal Cancer Trust In May 2024, has led to an unprecedented Increase In demand for Ask Eve over the last 12 months. There has been a 676% Increase In ceNlcal related querles, 155% Increase In other contacts alongslde slgnlflcant Increase In the complexlty of contacts. Many people concerned about symptoms and experlenclng slgnlficant delays In appolntments, Inve5tlgatlons and treatment contact Ask Eve for InformatSon, slgnpostlng, and support. Desplte thls huge Increase, Ask Eve has malntalned a 100% "extremely satlsfled" rate from servlce users. To address the growlng pressure on the servlce. fundlng has been secured and a scoplng exerclse undertaken to develop an Al tool to enhance efflclency, expand capaclty, and Improve accesslblllty. The tool wlll help trlage and manage slmple querles, 8llowlng our Ask Eve speclallst nurses to focus on more complex cases, ultlmately Improvlng the quallty and tlmellness of support provlded to Indlvlduals concerned aboLrt thelr gynae heafth. Ask Eve Is accessed by phone. emall, on-llne contact form. or Teams calls under speclflc clrcumstances. Bl-monthly onllne drop-ln sesslons were held through 2024, Ilnked to cancer awareness weeks, months, eampalgns and servlce user feedback. Ask Eve contlnues to offer Immedlate access to translatlon servlces, BSL and easy read materlals to support accesslblllty. Servlce users value the opportunlty to tslk through thelr concerns In detail and recelve the Indlvlduallsed Informatlon and support they need. as well as empowerment so they can advocate 15
Gynaecology Cancer Research Fd Annual Report Incorpor8tlng a Dlrectors. Rewt and Accounts for the year endlng 31 December 2024 for thelr own gynae heafth. The average tlme spent on a slmple phone or emall response is 19 minutes, twlce as long as a GP consultatlon. The average tlme spent on a complex phone or emall response Is 42 mlnutes. four tlmes longer than a GP appolntment. In Aprll 2024. our Ask Eve Co-ordlnator attended Wlndsor Castle for her MBE Investiture and In November 2024, was runner-up in the Helplines Partnership, Employee of the Year category. Informatlon and Awareness Information and Awareness is a key plllar of our work at The Eve Appeal. Across the whole year our gynae health informatlon webpages had over148,700 vlews. Our soclal posts, which contaln vltal gynae health Informatlon, reached over 750,800 people. We also ran ads across soclal medla and google to try Increase awareness of gynae cancers whlch were seen over 1,495,000 times. The Eve Appeal was mentloned In the medla 981 tlmes In 2024. 66% more than In 2023. The tltles we were mentloned In have a potentlal reach of16.1 bllllon. These 8rtlcles shared key gynae health Informatlon, how people can get support from our Ask Eve Nurses and commented on key storles Sn the news. Key outlets Include BBC Onllne, Mall OnlSne. Guardlan Onllne. The Independent, The Sun Onllne, Telegraph, Express, MSrror Onllne, Metro, Cosmopolltsn Onllne, ITV Onllne, Yahoo! News UK & Ireland, and Women's Health UK Onllne. 2024 Publk Aw•r•n•M and Edu¢atlon Campalgns C•rvI1 C•n¢•r Pr•v•nllon W••k Thls year we shared new Informatlve Illustratlons showlng what to expert from each stage of the ervlcal screenlng Journey- fiom the screenlng test, colposcopy through to LLETZ. We also shared our Informatlon and tlps for cervlcal screenlng In Easy Read. Across the week our soclal medla Posts reached over 85,000 people. The UK'S leadlng charlty for people wlth a learnlng dlsablllty, Mencap, also publlshed our Easy Read guldes on HPV and cervlcal screenlng on thelr webslte. Thls wlll help our Informatlon reach people wlth a learnlng dlsablllty and help support them to attend ceNlcal screenlng. Ovarlan Cancer Awarenem Month Thls Ovarl8n Cancer Awareness Month we launched Easy Read Informatlon on ovarlan cancer to help people wlth a learnlng dlsablllty or where Engllsh Isn't thelr flrst language access Ilfe-savlng Informatlon. Get Llppy CaMlon Thls Get Llppy our survey {YouGov) found that less than half of the women we suwveyed would get bleedlng after the menopause checked by a doctor {45%1. We also created tips to help women and people wlth gynae organs look after thelr health. The campalgn reached 1.25M people on soclal medla- a record year! CeNlcal Scr•enlng Awaren••s W••k For Cervlcal Screenlng Awareness Week we shared tlps on how to make yourself feel more comfortable durlng a cervlcal screenlng test, especlally If you have any barriers that make the test partlcularly difficult. We worked with many partners to create tailored content for our mutual audlences such as The SurvSvor's Trust, Vaglnlsmus Network and the Endometriosis Foundation. Our information was seen 649,000 times over the week across our webslte and soclal medla. We also had adverts In 70 GP surgeries across the country. 16
Gynaecology Cancer Research Fund Annuol Report Incorporatlng a Dlrectors. Report and Accounts for the year endlng 31 Deceml)er 2024 Gynaecologlcal Cancer Awareness Month This Gynae Cancer Awareness Month we focussed our Information on helping people know what was normal for their body, so that they are better able to spot when something changes that might need checklng by a doctor. We also launched a self-check monthly text reminder servlce to remind people to check thelr vulva, along with informatlon on how to check yourself and what to look out for. Nearly 2,000 people signed up to our texi remlnder service. Over 502.200 people saw our Informatlon on our soclal channels, and It was In the medla 280 tlmes. Includlng In: Inews. BBC The Inde ndent, Cosmopolltsn and The Sun. Outreach Following our 2023 pllot outreach wlth South Aslan Communttles In London, Blrmlngham and Manchester. we began a new pllot outreach reachlng Black Communities In the UK. The project was deslgned to be communlty-led, co-produced, and flexlble to accommodate the diverse needs and preferences of dlfferent communltles. We ran a total of nlne workshops wlth over 50 women across London and Manchester, dellvered by doctors who work across women's health and gynaecology, After the sesslons 87% of partlclpants rated themselves as havlng a "good" or "very good" understandlng of the toplcs. On average partlclpants Increased thelr knowledge by 37%. Slnce our pllot project, our Ask Eve nurse Inforrnatlon seNlce has seen 167% Increase In contacts from the Black communltle5, 66 F••llng very confldent and comfortable In kn¢)wlng what to look for and what to ask doctor wh•n n••d b•. In May. In partnershlp wlth NHS Cheshlre and Merseyslde Cancer Alllance and Improvlng Me, a Women's Health and Maternlty Programme based In the area. gynaecologlcal cancers and gynae health Informatlon sesslons were dellvered to South Aslan women In Llverpool. Of the women who answered our feedback questlonnalres, 30% felt they had a good or a very good understandlng of the toplcs before the sesslon, whlch rose to 89% after taklng part In the workshopl Th•r• n••d to b• mor• ot th• •S1O• wlthln the communl North East London Outr•ach Programm - You Need to Know In 2023 we ran a Jolnt local campaign wlth the North East London Cancer Alllance to ralse awareness of abnormal bleeding as the red flag symptom of womb cancer In Black and south Aslan women across the North East London boroughs. In 2024 the campalgn won Bronze at the PM Society Awards for Diversity and Inclusion in Creatlve Comms. The campalgn has also been taken up by the South East London Cancer Alllance and In 2024 we ran our first sesslon wfth them. wlth more planned for You Need to Know In 2025. 17
Gyrbgecology Cancer Research Fund Annual Report InCp(al1n9 a Dlrectors. Report and Accounts for the year endlng 31 December 2024 Health Infomwtlon We know that not havlng access to approprlate Information is one of the barrlers preventing underseNed communltles access tlmely healthcare. leadlng to a later dlagnosls of gynae cancer and sadly, worse outcomes. We are a PIF TICK approved health Information provider and have a clear focus on addressing health Inequalities by provldlng engaglng and easy to understand Information for the people who need it most. In 2024 we launched a brand-new website. with accessiblllty at Its heart. We revamped all of our heafth Informatlon on the webslte. maklng It easler to flnd, easler to understand and easier to get further support or Informatlon. We also launched Easy Read Informatlon on each of the flve cancers. These guldes wlll help people wlth a learnlng dlsablllty, or people where English isn't their flrst language, access and understand our Ilfe-savlng Informatlon. We also worked wlth GSK to translate our Jolnt Be Gynae Aware guldes Into four languages: Bengall. French, Urdu and Arablc. These guldes share key Informatlon for people to know thelr body and the key slgns and symptoms of the flve gynae cancers, as well as practlcal tlps to get the most out of a GP appolntment. Fundralslng From th• G•n•ral Publlc We are overwhelmed by the contlnued support of all those who choose to donate and fundralse towards our work durlng the year and the dlfference they are maklng. Whether taklng on vlrtual challenges, runnlng marathons or donatlng In response to our appeals, generous people across the UK and beyond contlnued to pull together and do what they could to help stop gynaecologlcal cancers before they start. Glfts from the general publlc account for the vast majorlty of our Incorne and so It Is only thanks to these Insplrlng and generous Indlvlduals that we can fund world-class research, our cancer Informatlon seNlce Ask Eve and our vltsl awareness ralslng work. We are also touched by the Incredlble 5UPPOrters who chose to Include a glft to The Eve Appeal In thelr Wlll. These glfts make a real and lastlng dlfference that wlll benefit all those affected by gynaecologlcal cancers for generatlons to come. It's an Incredlble legacy to leave. From Buslnesses We are truly thankful for the ongolng support of our long-term corporate p8rtner5, Includlng Tesco, Cosmetlc Executlve Women UK (CEW), League Manager's Assoclatlon and Saks Halr and Beauty Salons, who contlnue to support The Eve Appeal In so many ways. We are also Incredlbly grateful to all of those buslnesses that chose to support us durlng 2024, and especlally to Dalsh's and Boux Avenue who selected us as thelr Charlty of the Year and to MSD UK and Hologlc for thelr ongolng partnershlps. From Tru•ty Foundatlons and Statutory Fundlng 2024 was the flnal year of our fundlng from the Department of Health and Soclal Care to dellver our Every Woman Promise workplace programme to Small and Medlum Slze Enterprises (SMES). Thls programme has made a huge difference to those In these companles and we are extremely grateful for the opportunlty to dellver thls programme of work. We would Ilke to thank all Trusts who supported us durlng 2024. and especlally St James. Place for their multi-year fundlng. brlnglng stsblllty and securlty to our Ask Eve seNlce. 18
Gynaecology caer Research Fund Annual Rewt Incorporatlng 8 Dlrectors. Report and Accounts for the year endlng 31 December 2024 Impact Despite the many challenges of capturlng the Impact as a small medlcal research and advocacy charity. we continue to support real change - In transformatlve research dlscovery. cllnlcal practlce, accessing appropriate care, developing a broader understandlng about gynaecological health, reaching women who are not SUPPOrted, and in breaking down the barriers that women face managing their heatth. Impact can be dlfflcult to Judge through numbers alone; success can mean a slngle call encouraglng someone to attend a cervlcal screenlng appolntment or feaslblllty fundlng to a small- scale research proJecL Our relatlvely small research Investments have enabled our researchers to leverage slgnlflcant follow-on funds from natlonal and Internatlonal fundlng bodles. New 8W8rds made In the past 12 months provlde the foundatlons of novel research that could make qulcker dlagnosls and uftimately Improve treatment outcomes. It Is partlcularly gratlfylng for all of our stakeholders to see that rlskler research, supported In the early days, has many years later led to Important changes In cllnlcal practlce. Thls was a slgnlflcant year for Eve, for recognotlon and honourlng leadershlp In the research and advocacy sector: Awarded the Dlcey Scrogglns Dlstlngulshed Advocacy Award at the Internatlonal Gynaecologlc Cancer Soclety Conference In Dublin In October 2024. Our Ask Eve nurse servlce coordlnator. Helen Hyndman recelvlng an MBE In recognltlon of her servlces to those affected by gynaecologlcal cancers, Recelvlng the Health Educatlon Vlslonary Award, along wlth our Communlcatlons Manager. Lydla Braln. recelvlng 8 Speclal Commendatlon for Excellence In Soclal Medl8 Health Advocacy at the Cura-H awards. honourlng exceptlonal women dolng ploneerlng work In the healthcare Industry. Changlng Cllnlcal Practlce In 2024 the NICE guldellnes on Identlfylng and managlng famlllal and genetlc rlsk for ovarlan cancer were updated. Thls marks a transformatlve moment In healthcare and The Eve Appeal's research contrlbutlons were plvotal In thelr development. Spearheaded by Professor Ranjlt Manchanda. an Eve fellow, and wlth board member Professor Adam Rosenthal on the committee. The guldellnes lower the threshold for offerlng rlsk-reduclng surgery, a change that could save Ilves by Identlfylng at-rlsk Indlvlduals earller. This shift is expected to have a substantial Impact on the NHS. Many of The Eve Appeal-fvnded studles not only contrlbuted background data but provlded key evldence supportlng specific recommendations. These guidelines represent a major step forward In ovarlan cancer preventlon and risk management, and they are a testament to The Eve Appeal's long-stsndlng dedication to improving outcomes for women at risk of ovarian cancer. 19
Gynaecology Cr Resewch FurKI Annual Report Incorporatlng a Dlrectors. Report and Accounts for the year endlng 31 December 2024 The small grant fundlng from Th• Ev• App•al made thls work poHlbl•. •nabllng rnpr•Mntatlon of many Indlvlduals from acros• the communlty. Thls •tudy h•s Influen¢•d publ1¢ pollcy around the publlclty and r•crultm•nt to th• NHS England pllot J•wl•h populallon BRCA g•n•tlc t•stlng programm•. Thls wlll help •nsure all memb•r• of the publlc who are ellglble for thls program are conslder•d. Includlng hardty reKh•d and tradttlonally und•r-serv•d Th• Impad of The eve Appeal's seed fundlng has been tran•ft4rmatlve, creatlng a powerlul multlpll•r •ff•ct that acc•l•rats• rereh progress In gynaecologkal canc•r& W• ar• d••ply grat•ful to The Eve App••l. who wer• th• flr•t to b•ll•v• In and flnanclalty support our vlilon tor a d•dlcat•d reMarch rOre• for small ¢•ll ovarlan canc•r. Th• progr•ss mad• In th• Ilv• y•ari ilnc• hai be•n notlc••bl to UA. wlth awar•n•is and recognltlon ol Small cdl ai a dlstlnct form of ovarla c•nc•r growlng vlslbty throughout th• m•dlcal communlty. Ther• l• •tlll a lot r•s•arch work to b• don• to Improv• th• outcom•• of thls d•adty dlseas•. but wfth mor• h•althcar• provld•rs awarn. and mor• wllllng rn•oarch partl¢lpants r•w•r¢h progr•ss l• acc•leratlng. W• can look forward to a day when w• a¢hl•v• our go•1 to d•v•lop •ll•ctlv• treatrn•nts and Mv• Ilv•• for small ¢•ll ovarlan anc•r patl•nts, and w• ar• grat•ful that w• Can r•ly on th• •upport o Th• Ev• App••l and th•lr d•dlcat•d donor• unlll w• g•t th•re. -Pr•f•swr Wllllam Foulk•s. MCGIII Unlv•r•lty Informatlon and Awarenes• Impact Year-on-year our Impact and reach Is contlnulng to grow thanks to our wonderful supporters and communlty. Wlth hundreds of thousands of vlews to our webslte and mllllons of vlews across the medla and our soclal medla channels. The Eve Appeal has become the 'go-to' source for honest. trusted, health Informatlon and support. As we contlnue to grow our pool of Informatlon and work hard to get It to the people who need It most, we are grateful for the support of our partner organlsatlons who help us reach thelr communltles who currently face b8rrlers to healthcare. From other charltles. grass roots communlty organlsatlons. falth groups. and our wonderful medlcal advocates. women and people affected by gynae cancers, ambassadors. and supporters - everyone who has helped worked wlth us or share our Informatlon Is helplng to reallse our vlslon of a world where all gynaecologlcal cancers are prevented or detected at an earty stsge. Ask Eve Nurs• Servle• Impact The Increaslng number of contacts to Ask Eve and feedback obtalned from our serrflce user satisfaction questionnalre clearly demonstrates the Impact and value. People are often signposted to us from GP'S. practlce nurses. speciallst gynae nurses. other health professlonals. charlty organlsatlons. family members and frlends. Ask Eve Is a reputable. trusted source for evldence based gynae health Informatlon and support, Wlth empathy. understandlng. compasslon and care. Ask Eve has helped many facing e)rtraordlnary challenges. provldlng a Ilfeline to those concerned about gynae heafth and faclng long walts for care. The testlmonlals from servlce users attest to thls. 20
Gynaecology Cancer Research Fund Amual Report IncoTporatlng 8 Dlrectors. Rewt and Accounts for the year endlng 31 December 2024 l annot t•ll you how much It has mmnt to h*v• be•n Il•tM•d to •nd shown Ch gr•at ¢omp••slon. Your p•Mlon •hows In h¢>w you tr•at p•tl•nts and lamlll•s, and your oryanlmtlon ar• very fortun•t• to h•v• Such a wond•rful Nur•• Coordlnator. Thank you •g•ln. You h•v• h•lp•d m• and my daught•r wh•n w• n••d•d It. and I wlll b• for•v•r grat•ful. 66 Ask Eve Is meetlng the needs of Its users at a tlme when servlce demand Is the hlghest It has ever been. The Implementation of our Al tool and volunteer support wlll enable the contlnued dellvery of a hlgh quallty, accesslble and Incluslve seNlce. reachlng and meetlng the needs of as many people as posslble whllst contlnulng to demonstrate Impact. We are grateful to everyone who supports Ask Eve and contrlbutes to fts development and success. The added value of Ask Eve Is summed up by one of our users: Nothlng but pr41•• •nd th4nks ft4r th• a¢e•Mlblllty to a v•ry Inlormatlv• and v•luabl• r¥I¢• that could •av• or chang• p•opl•'• Ilv•g. Structure, Governance and Management Organlmtlonal •tructur• and deCIOn maklng The Charlty Is governed by a Board of Trustees who are members and also dlrectors of the Charlty for the purposes of the Companles Act. The Board sets the strateglc dSrectlon of the Charlty, ensurlng that the charltable purposes of the Charlty are met. Day-to-day runnlng of the Charlty Is delegated by the Board to the Chlef Executlve Officer. The Eve Appeal conslders each of the Trustees to be Independent In character and Judgement and understands that they have no relatlonshlps that are Ilkely to affect. or could appear to affec( thelr Judgements wlth regard to the Charlty. Declaratlons of Interest are requlred from new Trustees upon appolntment and every meetlng of the Board requlres that any new Interests are declared. No remuneratlon Is provlded except for reasonable travel and subslstence costs; In 2024 thls flgure was £0. There are two Commlttees whlch make recommendatlons to the Board: the Flnance & Audlt Commlttee and the Research Commlttee. The purpose of the Flnance & Audlt Commlttee Is to ensure that a strateglc approach Is taken In the areas of flnance, rlsk, audlt, remuneratlon and other operatlonal areas. The Finance & Audlt Commlttee Is comprlsed of at least four members. all of whom are Trustees, who glve detailed conslderatlon, on behalf of the Board, to these matters. The Research Commlttee provldes scientific research advlce and works on the recommendatlons of the external Research Advisory Committee for new funding decisions. These recommendatlons are viewed in light of the charity's mission. charitable objectives and financial posltlon. and the commlttee makes recommendatlons and provides advlce to the Board of Trustees. The Charlty had one 100% owned subsidiary company In the year. Eve Appeal Llmlted Ss a tradlng company that distributes its profrts under Glft Aid to the Charty. 21
Gynoecology Cancer Research Fund Annual Report Incorporallng a Dlrectors. Report and Accounts for the year endlng 31 December 2024 In 2021. in recognition of the Charity's support for key support programmes. the Prlnclpal Investlgator. Professor Martln Wldschwendter. gifted The Eve Appeal shares In a company. Sola Dlagnostlcs GMBH. whlch wlll be taking forward Innovatlve dlagnostlc tests whlch are at an early stage of development Any proflts arlslng from the venture wlll be fed back Into academlc medlcal research programmes. In 2023 Sola Dlagnostlcs GMBH had yet to make a profiL Truste• app•lnlment, Inductlon and tralnlng Trustees are appolnted In accordance wlth the Memorandum and Artlcles of Assoclatlon, taklng Into account the benefrts of appointing a person who Is able. by virtue of his or her personal or professlonal qualifications and experience. to make a contrlbutlon to the pursult of the objects or the management of the Charity. Trustees and staff conslder the skllls gaps formed by departlng Trustees and both openly advertlse for and nomlnate approprlate Indlvlduals wlth skllls to match before recommendatlon to Board for appolntment. References are taken before appolntment Ss formallsed and prospectlve Trustees are then proposed and appointed at the AGM. The Charlty undertakes a comprehensive Inductlon programme for all new Trustees, whlch Includes Inductlon materlals relatlng to its purposes and flnances, the powers and dutles of the Trustees and Informatlon about day-to-day runnlng of The Eve Appeal. Key documents are provlded, such as the Memorandum and Artlcles of Assoclatlon, the Charlty Commlsslon's Essentlal Trustee gulde, up-to- date accounts, and mlnutes of the most recent Trustee meetlngs. Prospectfve Trustees may also attend relevant Trustee meetlngs as an observer as part of the Inductlon process alongslde Introductlons to key people and places. Trustees contlnue to be supported through ongolng tralnlng, wlth sk1115 requlrements regularly revlewed. The Tru•t••s who Serv In th• p•rlod under r•vl•w w•rv. Melanle Rlchards CBE {Chalr of Trustees) (Reslgned, 07102124) Tamara Box (Appolnted 0110712020) (Chalr of Trustees effectlve 0810212024) (Appolnted 0411112019) (Reslgned 0510212025) (Appolnted 2611012020) (Appolnted 2910512022) (Reslgned 25101124) (Appointed 1911212019) (Appolnted 2711012021) (Appolnted 0411112019) (Appolnted 2611012020) (Appolnted 1811012023) (Reslgned 2310112025) (Appolnted 1811012023) (Appointed 0510212025) Sarah Clark lan Drew Dr Chrlstlne Ekechl Prof lan Jacobs Sldonle Klngsmlll Sarah Morris Marlon O'Hara Cathy Plttham-wlley Prof Adam Rosenthal Sally Balley Dee Brecker Emma Dean Helen Byrne Declaratlon of Interests All Trustees and staff are requlred to declare thelr Interests, and any payments (Includlng, but not Ilmlted to. beneflts In klnd such as glfts. hospltallty shopplnghravel concessions. preferential treatment, etc) recelved In connection with their role In The Eve Appeal where such Interests would. or mlght. confllct wlth, or Otherwo Influence thelr declslon-maklng In respect of the Charlty's activities. 22
Gynaecology Cancer Research Fund Annual Report Incorporallng a Dlrectors. Report and Accounts for the year endlng 31 December 2024 Wlth thanks to all members of the Research Advlsory Committee: Nam• Occupatlon and Oryanlsatlon Date of appolntment Professor Emma Crosble (Chair) Professor of Gynaecologlcal Oncology Manchester Unlversty Lead Gynae Oncology Cllnlcal Nurse Speclallst Royal Devon Unlverslty Healthcare Trust Lay/Communlty Representatlve Laylcommunlty Representatlve January 2024 Mrs Rhea Crlghton January 2021 Dr Helen Howle January 2021 Professor Sudha Sundar Professor of Gynaecologlcal Cancer, Unlverslty of Blrmlngham Emerltus Professor of Women's Cancer Professor Anne Lanceley Care, Instltute for Women's Health, Unlverslty College London Senlor Lecturer, Prlmary Care Cancer Research, Woltson Instltute of Populatlon Health, Queen Mary Unlverslty of London Honorary Profe55or, Instltute of Cancer and Genomlc Sclences, Blrmlngham Unlverslty; Consultsnt Gynaecologlcal Pathologlst Professor of Ovarlan Cancer Medlclne In the Professor James Brenton Department of Oncology, Unlverslty of Cambrldge June 2019 June 2024 Dr Garth Fun5ton June 2024 Professor Rajl Ganesan June 2024 May 2025 Staff A Senlor Management Team comprlslng the Chlef Executlve, the Dlrector of Fundralslng, the Head of Flnance and Head of Programmes allows for dlstrlbutlon of organlsatlonal responslblllty and both staff and Trustees contlnue to be happy wlth the structure. The CEO h85 partlcular responslblllty for Issues relatlng to governance and for the flnanclal management of the organlsatlon. The Eve Appeal has 20 permanent members of staff and the Trustees record thelr appreclatlon of the efforts of the staff. who have agaln made an enormous contributlon to the success of The Eve Appeal and Its mlsslon durlng the year. Volunts•rs and Advocat Volunteers and advocates play an essentlal role In shaplng and drlvlng The Eve Appeal's mlsslon. They share thelr personal experlences, support our research, revlew our health Informatlon, engage wlth the medla. support fundralslng and act as medlcal advocates across a range of activity. Their contributions ensure that our work remalns patlent-centred, impactful and far- reachlng. As we grow. we are committed to fostering a more structured and Incluslve approach to volunteer engagement, recognising the vital role that Eve Voices play across our research. awareness and outreach efforts. By embedding meaningful involvement Into our work, we aim to bulld a strong. empowered network that contributes to research, health education and advocacy in a way that benefits both the charty and those involved. 23
Gynaecol¢)gy Cancer Research Fund Amuol Report Incorporallng a Dlreclors, Report and Accounts for the year endlng 31 December 2024 We are hugely proud of our rnany advocates and thelr pass5on and engagement In the charlty. We are also proud of our support of these volunteers to date and the close communlty that we have fostered. We are working to build on this strong foundation and develop clear frameworks to support. traln and recognlse our volunteers. ensurlng that their time and expertlse are valued. By strengthenlng our systems for engagement and Impact measurement. we wlll contlnue to bulld a charlty that not only listens to Its communlty but thrlves because of ft. Our volunteers and dvocates are the heart of our work. and thelr volces wlll shape the future of gynaecologlcal cancer preventlon and early detectlon. Equlty, Dlv•rslty and In¢lu•lon Equallty. dlverslty and Incluslon Is at the heart of everythlng we do. Gynaecologlcal cancers can have a negatfve Impact on anyone's Ilfe. That's why we make sure our research, educatlonal campalgns and free. expert Informatlon and advlce are focused on helplng everyone who could be affected by a gynaecologlcal cancer. We want to prevent every slngle case of gynaecologlcal cancer posslble. To do that we know that addresslng health Inequalltles Is central to our mlsslon. We work wlth dlverse communftles across the UK to ralse awareness of gynaecologlcal cancers. to gulde our research projects and our pollcy dlscusslons. We're unwaverlng In our commltment to foster an envlronment where equlty Is promoted. dlverslty Is valued and celebrated, and everyone feels Included. We're gulded by our values and contlnuously learn and adapt to ensure EDI Is embedded In everythlng we do. We Invlte 811 our partners, suppllers and supporters to Joln u5 In thls work. Saf•guardlng Pollcy All staff and Trustees have been offered tralnlng. We have a safeguardlng le8d Trustee and a clear escalatlon process In place. Safeguardlng Issues and concerns are notlfled to the Board as part of the quarterly reportlng process. The Eve Appeal Is commltted to valulng dlverslty, preventlng dlscrlmlnatlon and achlevlng equallty of opportunlty. The Eve Appe81 belleves everyone has the rlght to Ilve free from abuse or neglect regardless of age, ablllty or dlsablllty, sex, race, rellglon, ethnlc orlgln, sexual orlentatlon. marltal or gender status. The Eve Appeal wlll not dlscrlmlnate on the grounds of domestlc clrcumstsnces, educatlonal or soclal-economlc status. polltlcal affillatlon, or trade union membershlp. The Eve Appeal Is commltted to creatlng and malntalnlng a safe and posltlve envlronment and an open. Ilstenlng culture where people feel able to share concerns wlthout fear of retrlbutlon. The Eve Appeal acknowledges that safeguardlng Is everybody's responslblllty and Is commltted to preventlng abuse and neglect through safeguardlng the welfare of all adults Involved. The Eve Appeal recognises that health. well-being, abillty. dlsabillty and need for care and support can affect a person's reslllence. We recognlse that some people experience barriers. for example. to communication in raislng concerns or seeklng help. We recognlse that these factors can vary at dlfferent points In people's Ilves. Safeguarding actions taken by The Eve Appeal wlll be conslstent with the prlnclples of adult safeguarding ensurlng that any action taken Is prompt. proportlonate and that It includes and respects the voice of the adult concerned. 24
Gynaecology Cancer Resewch Fund Annual Report Incorporadng a Dlrectors. Report and Accounts f¢x the year endlng 31 Oecernber 2024 Flnanclal Revlew 2024 Transactlons and Flnanclal Posltlon At December 2024 year end. we reported a surplus of £470.402 (2023: £362.326) in unrestricted reserves to carry forward Into 2025. Thls surplus comprlses funds of £290.402 above our agreed operating reserves level of £180.000. In 2023 we Introduced a Research Fellowshlps Programme, supportlng our legacy programme wlth Prof. Martln Wldschwendter, as well as holdlng a research open call. We have an ambltlous programme for 2025 grant awards. Endlng 2024 wlth substantlal unrestrlcted reseNes places The Eve Appeal In a posltlon to meet our award ambltlons. In summary, we begln 2025 In a cautlous but stsble posltlon wlth £470,402 In unrestrlcted funds. Thls leaves £290,402 In free reseNes. Free reserves are the unrestrlcted funds balance mlnus the operatlng reserves level of £180,000. At end of 2024 overall cash balance was £1,060,129. Fundlng Fundralslng pollcy Sectlon 162a of the Charltles Act 2011 requlres charltles to make a statement regardlng fundralslng actlvltles. The leglslatlon defines fundralslng as 'sollcltlng or otherwlse procurlng money or other property for charltable purposes.. Such amounts recelvable are presented In our accounts as 'donatlons and voluntary Income,. We conflrm that all sollcltatlons are managed Internally. wlthout Involvement of commerclal partlclpators or professlonal fundralsers or thlrd partles. The day-to-day management of all Income generatlon Is delegated to the executlve team, whlch Is accountable to the Trustees. We have recelved no complalnts In relatlon to fundralslng actlvltles. The Eve Appeal Is funded prlnclpally by voluntary donatlons from Indlvldu81s and communlty groups who contlnue to support our work and mlsslon. Corporate sponsorshlp and donatlons also ccount for a slgnlflcant proportlon of our fundlng. Wlthout thls support we would not be able to operate and we are Incredlbly grateful for every penny that Is donated. Rlsk Management The Trustees have assessed the major rlsks to whlch The Eve Appeal Is exposed and are satlsfied that systerns are estsbllshed to mltlgate the Charlty's exposure to those rlsks. These rlsks are detalled on the Rlsk Reglster for The Eve Appeal. wlth Informatlon on the current practlce and strategy used to mltlgate the rlsk. The Register Is revlewed quarterty by Trustees. The current Rlsk Reglster pays partlcular attentlon to the rlsks around the current fundralslng envlronment and the on-golng economlc crlses on Income and operatlons, research not reachlng Intended objectlves. fundralslng targets belng mlssed, loss of key Indlvlduals. IT fallure (Includlng cyber securlty rlsk) and incorrect information being provided on a health issue. The Integrlty of medlc81 Informatlon provlded by the Charlty Is managed by agreed peer-revlewed protocols, wlth Informatlon standards applled across all materlals and channels. A balanced portfollo of fundralslng actlvlty spreads rlsk to reduce any potentlal Impact. Regular flnanclal plannlng, Includlng re-forecast of fundraising Income and expendlture. ensures early Interventlons can be made. 25
Gynaecolopy Cancer Research Fund AMU81 Report Incorporatlng a Dlrectors. Rewt and Accounts for the year endlng 31 December 2024 R•8•ms Pollcy The 2024 annual revlew of the reserves pollcy determlned that no adjustments was required to the figure set In 2023 of £180,000. The figure Is set by the Board as a target of holding £180,000 In free reserves. Thls tsrget Is based on the contingency for wind up finds, calculated to satisfy all the Charity liabilities In the event of closure. In real terms. £180,000 represents just under three months, budgeted expenditure, excluding expenditure on research grants and restricted charitable activities. We begin 2025 in a cautious but stable position wlth £470,402 In unrestrlcted funds. Thls leaves £290,402 In free reseNes which Is in addltion to operatlng reserve level of £180.000. The Board wlll contlnue to revlew the reserves pollcy annually to ensure It remalns approprlate to the needs of the Charlty In the context of the economlc cllmate. Oolng Con¢•rn The Trustees have revlewed the Charlty's flnanclal posltlon, taklng Into account the levels of reserves, cash, commltted Income Included In the accounts, future plans and Its systems of flnanclal and rlsk management. The Trustees belleve that the Charlty Is well placed to manage operatlonal and flnanclal rlsks successfully. Accordlngly, the Trustees have a reasonable expectatlon th8t the Ch8rlty has adequate resources to contlnue In operatlon for the foreseeable future and conslder that there are no materlal uncertalntles about the group's ablllty to contlnue as a golng concern. Or•nt M•klng Polky The pollcy of the Trustees Is to fund world-class medlcal research that wlll make the blggest Impact In savlng women's Ilves from gynaecologlcal cancers, Includlng fundlng proof-of-prlnclple work to enable the award of future fundlng. As a member of the Assoclatlon of Medlcal Research Charltles, we have developed 8 Strategy and fundlng declslon-maklng processes that meet strlct awardlng crlterla and revlew, and recommendatlons are made by Independent experts In the research fleld. ststement of Trustees, Responslbllltles The Trustees (who are 8150 dlrectors of Gynaecology Cancer Research Fund for the purposes of company lawl are responslble for preparlng the Trustees, Report and the flnanclal statements In accordance wlth appllcable law and Unlted Klngdom Accountlng Stsndards (Unlted Klngdom Generally Accepted Accountlng Practlce). Company and charlty law requlres the Trustees to prepare flnanclal statements for each flnanclal year. Under company law the Trustees must not approve the flnanclal statements unless they are satlsfled that they glve a true and falr vlew of the state of affalrs of the charltable company and the group and of the incoming resources and applicatlon of resources. Includlng the Income and expendlture, of the charltable group for that period. In preparlng these flnanclal statements. the Trustees are required to: select sultable accountlng pollcles and appty them conslstently; observe the methods and prlnclples In the Charftles SORP (FRS 102); make Judgements and estimates that are reasonable and prudent; 26
Annual Report Incorporallng a DlrecioryJ' Report and AcCots for the year endlng 31 December 2024 state whether appllcable UK Accountlng Stsndards have been followed. subject to any material departures disclosed and explalned In the financlal statemerrts: prepare the financlal statements on the golng concern basls unless It Is Inapproprlate to presume that the charitsble company will continue in buslness. The Trustees are responsible for keeping adequate and proper accounting records that are sufficlent to show and explain the charltable company's transactions and dlsclose with reasonable accuracy at any time the financial positlon of the charltable company and enable them to ensure that the flnanclal statements comply wlth the Companles Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charltles Accounts (Scotland) Regulatlons 2006 (as amended). They are also responslble for safeguardlng the assets of the charitsble company and the group and hence for tsklng reasonable steps for the preventlon and detectlon of fraud and other Irregularltles. In so far as the Trustees are aware: there Is no relevant audlt Informatlon of whlch the charltable compary's audltor Is unaware: the Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audlt Informatlon and to estsbllsh that the audltor Is aware of that Informatlon. The Trustees are responslble for the malntenance and Integrlty of the corporate and financlal Informatlon Included on the charltable company's webslte. Leglslatlon In the Unlted Klngdom governlng the preparatlon and dlssemlnatlon of financlal statements may dlffer from leglslatlon In other Jurlsdlctlons. Thls report has been prepared In accordance wlth the speclal provlslons relatlng to small companles wlt n Part 15 of the Companles Act 2006. If of the ar Tam Box. Chalr iYIDsI Date.. 27
Gynaecology Cancer Research Fund Annual Report Incorwatlng a Dlrectors. Report and Accounts for the yew endlng 31 December 2024 Independent Audltor's Report to the Trustees of Gynaecology Cancer Research Fund Oplnlon We have audlted the financlal statements of Gynaecology Cancer Research Fund ('the parent charltable company,) and its subsidiaries (the 'group') for the year ended 31 December 2024 whlch comprise the Group Statement of Financial Actlvities (including the Group Summary Income and Expendlture Account), the Group and Parent Charitable Company Balance Sheets, the Group Cash Flow Statement and notes to the flnancial statements, including significant accountlng pollcles. The flnanclal reportlng framework that has been applled In thelr preparatlon Is applicable law and Untted Klngdom Accountlng Standards, Including FRS 102 'The Flnanclal Reportlng Standard Appllcable In the UK and Republlc of Ireland, (Unlted Klngdom Generally Accepted Accountlng Practlce). In our oplnlon the financial ststements: glve a true and falr vlew of the state of the group's and the parent charltable company's affalrs as at 31 December 2024 and of the group's Incomlng resources and appllcatlon of resources, IncludSng Sts Income and expendlture, for the year then ended; have been property prepared In accordance wlth Unlted Klngdom Generally Accepted Accountlng Practlce; and have been prepared In accordance wlth the requlrements of the Companles Act 2006, the Charltles and Trustee Investment (Scotland) Act 2005 {as amended), regulatlons 6 and 8 of the Charltles Accounts (Scotland Regulatlons 2006 (as amended) and the Charltles Act 2011. Ba• for oplnlon We conducted our audlt In accordance wlth Internatlonal Standards on Audltlng (UK) (ISAS (UK)) and appllcable law. Our responslbllltles under those standards are further descrlbed In the Audltor's Responslbllltles for the audlt of the flnanclal statements sectlon of our report. We are Independent of the charltable company In accordance wlth the ethlcal requlrements that are relevant to our audtt of the fln8ncS8l statements In the UK, Includlng the FRC'S EthScal Standard, and we have fulfllled our other ethlc81 responslbSlltles In accordance wlth these requlrements. We belleve that the audlt evldence we have obtalned Is sufflclent and approprlate to provlde a b8sSs for our oplnlon. Conclu8lons relatlng to golng concern In audlting the financial statements, we have concluded that the trustees, use of the golng concern b851s of accountlng In the preparatlon of the flnanclal statements Is approprlate. Based on the work we have performed, we have not Identlfied any materlal uncertalntles relating to events or conditlons that, Indlvldually or collectlvely. may cast slgnlflcant doubt on the charitable company's ability to continue as a going concern for a perlod of at least twelve months from when the financial statements are aLrthorlsed for Issue. Our responsibilities and the responsibilitles of the trustees wlth respect to golng Concern are descrlbed In the relevant sectlons of thls reporL Olh•r Infomiallon The other Information comprlses the Informatlon Included In the annual report, other than the flnanclal statements and our audltor's report thereon. The trustees are responsible for the other Information contalned withln the annual report. Our opinlon on the financlal statements does not cover the other Informatlon and. except to the extent otherwlse explicltty stated In our report. we do not express any form of assurance concluslon thereon. 28
Gynaecology Cancer Research Fund Annual Report Incorporallng a Dlrectors. Report and Accowts for the year endlng 31 December 2024 Our responslblllty Is to read the other informatlon and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtalned In the course of the audit or otherwise appears to be materially mlsstated. If we Identify such materlal Inconsistencies or apparent material misstatements, we are required to determlne whether there Is a material misstatement in the financial statements themselves. If. based on the work we have performed, we conclude that there is a material misstatement of this other Information, we are requlred to report that facL We have nothlng to report In thls regard. Oplnlon• on •ther matter• pr•Krlbed by the Compan1 Art 2006 In our oplnlon, based on the work undertaken In the course of the audlL' the Informatlon glven In the trustees. annual report for the financlal year for whlch the flnanclal statements are prepared Is conslstent wlth the financlal ststements; and trustees, annual report have been prepared In accordance wlth appllcable leg81 requlrements. Matter• on whl¢h w• ar• r•qulr•d to r•port by •xc•ptlon In the Ilght of the knowledge and understandlng of the company and Its envlronment obtalned In the course of the audlt, we have not SdentSfied materlal mlsstatement5 In the trustees. annual report. We have nothlng to report In respect of the followlng matters where the Companles Act 2006, the Charltles Accounts (Scotland) Regulatlons 2006 (as amended) and the Charltles Act 2001 requlres us to report to you If. In our oplnlon: adequate accountlng records have not been kept, or returns adequate for our audlt have not been recelved from branches not vlslted by us: or the flnanclal statements are not In agreement wlth the accountlng records and returns; or cert8ln dlsclosures of trustees, remuneratlon speclfled by law are not made; or we have not recelved all the Informatlon and explanatlons we requlre for our audlt; or the trustees were not entltled to prepare the flnanclal statements In accordance wlth the small companles reglme and take advantage of the small companles exemptlon In preparlng the tru5tees' annual report and from preparlng a strateglc report. R••pon•lbllttle• of tru•te•• As explalned more fully In the trustees, responslbllltles statement set out on page 27. the trustees {who are also the dlrectors of the charltable company for the purposes of company law) are responsible for the preparatlon of the financial statements and for belng satlsfied that they glve true and fair view, and for such internal control as the trustees determlne Is necessary to enable the preparatlon of flnanclal ststements that are free from materlal mlsstatement, whether due to fraud or error. In preparlng the flnanclal statements, the trustees are responslble for assesslng the charltable company's abillty to contlnue as a golng concern. dlscloslng, as applicable, matters related to going concern and uslng the golng concern basls of accounting unless the trustees elther Intend to Ilquldate the charltable company or to cease operatlons. or have no realistic alternative but to do so. Audltor's Responslbllltles for the audlt of the flnanclal statements We have been appolnted as audltor under Sectlon 4411)(c) of the Charitles and Trustee Investment {Scotland) Act 2005. the Companles Act 2006 and Sectlon 151 of the Charlties Act 2011 and report to you In accordance wlth regulatlons made under those Acts. 29
Gynoecology ccer Research Fund Annual Report Incorporatlng a Dlrectors. Report and ACCO for the year endlng 31 December 2024 Our objectives are to obtain reasonable assurance about whether the financlal statemerrts as a whole are free from material mlsstatement, whether due to fraud or error. and to Issue an auditor's report that Includes our oplnlon. Reasonable assurance Is a hlgh level of assurance. but is not a guarantee that an audlt conducted in accordance wlth ISAS (UK) wlll always detect a material misstatement when It exlsts. Mlsstatements can arise from fraud or error and are considered materlal if. individually or in aggregate, they could reasonably be expected to Influence the economlc declslons of users taken on the basls of these financlal statements. As part of an audlt In accordance wlth ISAS (UK) we exerclse professlonal Judgement and malntaln professional scepticism throughoLrt the audit. We also: Identlfy and assess the rlsks of materlal mlsststement of the financlal statements, whether due to fraud or error, deslgn and perform audit procedures responslve to those rlsks, and obtaln audlt evldence that Is sufflclent and approprlate to provlde a basls for our oplnlon. The rlsk of not detectlng a materlal misstatement resultlng from fraud Is hlgher than for one resultlng from error, as fraud may Involve collusion, forgery, Intentlonal omlsslons. mlsrepresentatlons, or the overrlde of Internal control. Obtaln an understandlng of Internal control relevant to the audlt In order to deslgn audlt procedures that are approprlate In the clrcumstances, but not for the purposes of expre551ng an oplnlon on the effectlveness of the charltable company's Internal control. Evaluate the approprlateness of accountlng pollcles used and the reasonableness of accountlng estlmates and related dlsclosures made by the trustees, Conclude on the approprlateness of the trustees, use of the golng concern basls of accountlng and, based on the audlt evldence obtalned, whether a materlal uncertalnty exlsts related to events or condltlons that may cast slgnlflcant doubt on the charltable company's ablllty to contlnue as a golng concern. If we conclude that a materlal uncertalnty exlsts, we are requlred to draw attentlon In our audltor's report to the related dlsclosures In the flnanclal statements or, If such dlsclosures are Inadequate, to modlfy our oplnlon, Our concluslons are based on the audlt evldence obtalned up to the date of our audltor's report. However. future events or condltlons may cause the charltable company to cease to contlnue as a golng concern. Evaluate the overall presentatlon. structure and content of the flnanclal statements, Includlng the dlsclosures, and whether the flnanclal statements represent the undertylng transactlons and events In a manner that achleves falr presentatlon. Obtaln sufflclent approprlate audlt evldence regardlng the flnanclal Informatlon of the entltles or buslness actlvltles wlthln the group to express an oplnlon on the consolidated flnanclal statements. We are responslble for the dlrectlon. supervlslon and performance of the group audlt. We remaln solety responslble for our audft report. We communlcate wfth those charged wlth governance regardlng, among other matters, the planned scope and tlmlng of the audlt and significant audlt findlngs, Including any significant deflclencles In Internal control that we Identify during our audlt. Explanallon as to what •xt•nt th• audft was eonsld•r•d Capab of d•t•ctlng Irregularltl• Includlng fraud Irregularities. including fraud. are instances of non-compllance w5th laws and regulatlons. We deslgn procedures In Ilne wlth our responslbilities. outlined above, to detect materlal mlsststementS in respect of Irregularltles, including fraud. The extent to wh5ch our procedures are capable of 30
Gynaecology Cancer Research Fund Annual Report Incowatlng a Dlrectors. Report and Attounts for the year endlng 31 December 2024 detectlng Irregularltles. Includlng fraud Is detslled below. The objectlves of our audlt In respect of fraud. are: to Identify and assess the risks of materlal misstatement of the financial statements due to fraud: to obtain sufflcient appropriate audlt evldence regardlng the assessed risks of materlal misstatement due to fraud. through designlng and implementing appropriate responses to those assessed iisks; and to respond appropriatety to Instances of fraud or suspected fraud Identlfied during the audlt. However, the prlmary responslblllty for the preventlon and detectlon of fraud rests wlth both management and those charged wlth governance of the charltable company. Our approach was as follows: We obt81ned an understsndlng of the legal and regulatory requlrements appllcable to the charltable company and consldered that the most slgnlficant are the Companles Act 2006, the Charltles and Trustee Investment (Scotland) Act 2005 (as amended), regulatlons 6 and 8 of the Ch8rStles Accounts (Scotland) Regulatlons 2006 (as amended), the Charltles Act 2011, the Charlty SORP, and UK flnanclal reportlng standards as Issued by the Flnanclal Reportlng Councll and UK tax leglslatlon. We obtalned an understandlng of how the charltable company complles wlth these requlrements by dlscussions with management and those charged wlth governance. We assessed the rlsk of materlal m155tatement of the flnanclal ststements. Includlng the rlsk of rnaterlal mlsstatement due to fraud and how It mlght occur, by holdlng dlscusslons wlth management and those charged wlth governance. We Inqulred of management and those charged wtth governance asto any known Instsnces of non-compllance or suspected non-compllance wlth laws and regulatlons. Based on thls understandlng, we deslgned speclfic approprlate audlt procedure5 to Identlfy Instances of non-compllance wlth laws and regulatlons, Thls Included maklng enqulrles of management and those charged wlth governance and obtalnlng addltlonal corroboratlve evldence as requlred. There are Inherent Ilmitatlons In the audlt procedures descrlbed above. We are less Ilkely to become aware of Instances of non-compllance wlth laws and regulatlons that are not closely related to events and transactions reflected In the flnanclal statements. Also, the risk of not detectlng a materlal mlsstatement due to fraud Is hlgher than the rlsk of not detectlng one resulting from error, as fraud may Involve dellberate concealment by, for example, forgery or Intentlonal mlsrepresentatlons, or through colluslon. of our r•port Thls report is made solely to the charltable company's members, as 8 body, In accordance wlth Chapter 3 of Part 16 of the Companles Act 2006; and to the Charty's Trustees. as a body In accordance wlth Sectlon 44(1)(c} of the Charltles and Trustee Investment {Scotland) Act 2005. and In respect of the consolldated flnanclal statements, In accordance wlth Chapter 3 part 8 of the Charities Act 2011. 31
Gynaecology Cancer Research Fund Annual Report Incorporaung a Dlrectors. Report and AcCots ts the year endlng 31 December 2024 Our audit work has been undertaken so that we mlght state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permltted by law. we do not accept or assume responsibility to any party other than the charitable company and charitable company's members as a body, for our audit work. for thls report. or for the oplnions we have formed. James Saunders. FCCA DCHA {Senlor Lrtory Audltor) for and on behalf of Moore Klngston Smlth LLP, Statutory Audltor 6th floor 9 Appold Street London EC3A 2AP Date: Moore Klngston Smlth LLP Is ellglble to act as audltor In terms of Sectlon 1212 of the Companles Act 2006. 32
Gynaecology Cancer Research Fund Annual Report Incorporallng a Dlrect¢yrs' Rep and Accounts for the year endlng 31 December 2024 Consolldated Statement of Flnanclal Actlvltles (Incorporatlng an Income and expendlture account) for the year ended 31 December 2024 Notes Unrestrlcted Restrlcted 2024 2023 Income Don8tlons and legacles Other tradlng actlvltles Investment Income Other Income Total 1,231,010 101.550 22.702 427.576 1,658,586 101,550 22.702 1,241,205 87,901 15,474 278 427.576 1.782.838 1.344.858 1.355.262 Expendlture RaisSng fund Charltable actlvlty Total 584,374 662 812 1.247.186 84 584,458 594,756 434 984 1097 796 1,005,524 435.068 1.682,254 1,600.280 Net Incomelexpendlture 108,076 {7.492) 100,584 (255,422) Transfers between funds Net movement In funds 108,076 17,492) 100,584 (255,422) Reconclllatlon of funds Total funds brought forward 362,326 319,461 681,787 937,209 Total funds carrled forward 311969 782 371 681787 All the above amounts relate to contlnulng actlvltles. 33
Gynaecology Qncer R¢sear¢h Fund Annual Rewt Incorporatlng a Dlrectorf Report and Accounts for the year endlng 31 December 2024 Consolidated and Charity Balance Sheet as at 31 December 2024 Group Charity Notss 2024 2023 2024 2023 Flxed assets Intsngible flxed assets Tangible fixed assets Investment 14 15 16 2,662 10,607 3,461 17,981 2,662 10,607 3,461 17,981 20,700 28,873 20,701 28,874 Current assets Debtors Cash at bank and in hand 17 201,221 1060 129 1,261,350 191,025 928 895 1,119,920 157,861 1029 414 1,187,275 180,863 1,022,340 Creditors: amounts falllng due 467 006 455 056 Net current assets 761,671 652,914 657,180 567,284 Net Assets 782 371 681787 677 881 596 158 Funds Restrlcted Unrestrlcted Total Funds 20 19 311,969 470 402 782 371 319,461 362 326 681787 311,969 365 912 677 881 319,461 276 697 596 158 As pemiltted by S408 of the Companles Act 2006, the company has not presented its own Income and expenditure and related notes. These financial ststements were approved by the Board of Trustees and authorised for Issue on 14 May 2025 ar were signed on its behalf by: Tamara Bo& Chalr Company No. 4370087 34
GyMecolo9y Cancer Researth FurKI Annual Report Incorporallng a Dlreclws, Report and Accourbts for the year endlng 31 December 2024 Consolldated Statement of Cash Flows for the year ended 31 December 2024 2024 2023 Cashflow from operatlng actlvltles Cash provlded by operatlng actlvftles 109,820 (151.812) Cash flows from Investlng actlvStSes Interest Income Purchase of tanglble flxed assets 22,702 (1,288) 15,474 (9,384 Net cash used In Investlng actlvltles 21.414 6.090 Change In cash and cash equlvalent In the perlod 131,234 928 895 1,060,129 <14S,722) 1074 607 928.885 st Cash and cash equlvalents at 1 January Cash and cash equlvalents at 31" December Reconclllatlon of net Incomelexpendlturel to net cash flow from operatlng actlvltles: Net Incomel(expendlture) for the perlod Adjustment for: Investment Income Depreclatlon Amortlsatlon Decreasel(IncTease) In stock Decreasel(Increase) In debtors (Decrease)Ilncrease In credltors 100,584 (255,422) (22,702) 8,662 799 (15,474) 3.564 799 250 95.406 19,065 (10.196) 32,673 Net cash provlded bylused In operatlng actlvttles 109.820 {151.812) Analysls of cash and cash equlvalent and net debts Cash In hand and at bank Openlng balance Cash flows 928,895 131.234 1,074,607 145,722 Closlng balance 1060 129 35
Gynaecology Cancer Research Fund Annual Report Incorporallng a Dlrectors. Report and Accounts for the year endlng 311)ecembef 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 1. GENERJL INFORMATK>N Company Informallon Gynaecology Cancer Research Fund, operatlng as The Eve Appeal, Is a publlc benefft entlty, a charlty registered In both England and Wales (reglstered charlty number 1091708) and Scotland (SC0462612), and a company Ilmlted by guarantee (company number 04370087). reglstered In England. The reglstered office and Its prlnclpal place of buslness Is The Eve Appeal, 10-18 Unlon Street, London, SE11SZ. 2. ACCOUNTING POLICIES (a) 8asl• ol pr•paratl¢ The flnanclal statements have been prepared under the hlstorlcal cost conventlon wlth Items recognlsed at cost or transactlon value unless otherwlse stated In the relevant note{s) to these fin8nclal statements. The financlal statements have been prep8red In accordance wlth the Accountlng and Reportlng by Charltles: Ststement of Recommended Practlce appllcable to Charltles preparlng thelr accounts In accordance wlth the Fln8nclal Reportlng Standard appllcable In the UK and Republlc of Ireland IFRS102) Includlng Update Bulletln 2, (Charltles SORP {FRS 102), the Flnanclal Reportlng Standard appllcable In the UK and Republlc of Ireland (FRS 102) and the Companles Act 2006. Gynaecology Cancer Research Fund constltutes a publlc beneflt entlty as deflned by FRS 102. The flnanclal statements are prepared In sterllng, whlch Is the functlonal currency of the company. Monetary amounts In these flnanclal statements are rounded to the nearest £1. The Trustees conslder that there are no materlal uncertalntles about the group's ablllty to contlnue as 8 golng concern. (b) Golng Concern The Tru5tee5 have assessed whether the use of golng concern Is approprlate and have consldered events or condttlons that mlght cast slgnlflcant doubt on the ablllty of the group to contlnue as a golng concern. The Trustees have gSven due conslderatlon to the current economlc uncertalnty and have reduced the rlsk wlth Income spread across dlfferent Stream of actlvlty. Havlng revlewed forecasts prepared by management the Trustees are confldent that the Charlty and the group wlll contlnue to meet Its obllgations as they fall due and that therefore the golng concern basls contlnues to be approprlate. 36
Gynaecology Cancer Resewch Fund Annual Report IncOrptIng 8 Dlrectors. Report and Accounts for the year endlng 31 December 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 ¢c> Group Flnanclal Statements These flnancial statements consolidate the results of the Charlty and Its wholly owned subsidiary, The Eve Appeal Limited, on a line-by-llne basis. The subsldiary company has the same year end date of 31 December 2024. (d> Fund Accountlng Unrestrlcted funds comprlse accumulated surpluses and deficlts on general funds. They are available for use at the dlscretlon of the Trustees In furtherance of the general charStsble objectlves. Deslgnated funds are unrestrlrted funds whlch are earmarked for a partlcular purpose. Restrlcted fund5 are funds subject to speclflc restrlctlons Imposed by the donors. l•) In¢om• Income represents amounts recelvable by the Charlty durlng the year from all sources. All Income Is Included In the Statement of Flnanclal Actlvltles when the charlty Is legally entltled to the Income and the amount can be quantlfled wlth reasonable accuracy. Legacles are accounted for when the Charlty has entltlement, recelpt Is probable. and the amount Is measurable, Donatlon5 are accounted for on a recelvable b8515. Other tradlng actlvltles are accounted for on a recelvable basls and In the year to whlch they relate. Donated servlces or facllltles are recognlsed when the Charlty has control over the Item, any condltSons assoclated wlth the donated Item have been met, the recelpt of economlc beneflt from the use of the Charlty of the Item Is probable and that economlc benefit can be measured rellably. (fj Exp•ndltur• & VAT Expendlture Is accounted for on an accruals basls and Is Incluslve of Irrecoverable VAT. Grants payable are charged to the Statement of Flnanclal Actlvltles when authorlsed by the Board of Trustee5 and communlcated to the reclplenL Charltable expendlture comprlses those costs Incurred by the Charlty In the dellvery of Its objectlves. It Includes both costs that can be allocated dlrectly to such actlvltles and the costs of an indlrect nature as necessary to support them. Costs of ralslng funds comprlse fundralslng costs and the costs Incurred In the subsldlary tradlng activities. Fundraislng costs Include advertlslng, produclng publlcatlons, prlnting and maillng fundralslng materlals, assoclated staff costs and an approprlate allocatlon of support costs. Support costs are those costs Incurred In support of the Charlty's prlmary objectlves and are allocated on the basls of staff tlme spent on those objectives. 37
Gynaecology Cancer Research Fund Annual Report Incorporatlng a Dlrectors. Report and Accounts the year endlng 31 December 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 Governance costs are those costs relatlng to compllance wlth constftutlonal and statutory requlrements and the structure and governance revlew and are allocated on the basls of tlme spent overseelng the relevant actlvltles. (g) Tanglbl• Flx•d AM•ts and Deprnclatlon Tanglble Flxed assets are recorded at cost less depreclatlon and ImpalrmenL Depreclatlon Is provlded on all tanglble flxed assets In order to wrlte off thelr cost by equal annual Instalments over thelr expected useful Ilves. The rate adopted for Flxtures and Flttlngs @ 25% on cosL (h) Intanglbh Flx•d Asmts and Amortl•atlon Amortlsatlon Is provlded on all Intsnglble fixed assets In order to wrlte off thelr cost by equal annual Instalments over thelr expected useful Ilves. The rate adopted for trademarks @10% on cosL 111 Inv••tm•nts Unllsted Investments comprlse the followlng: _ Investments In subsldlarles whlch are measured at cost less Impalrment. Investments In a Jolnt venture acqulred In the year under revlew. Under the charlty SORP thls Is measured uslng the equlty method of accountlng. The equlty method of accountlng requlres the assoclate to be Inltlally recognlsed at Its cost (the transactlon prlce pald). Includlng any cost Incurred maklng the Investment (transactlon costs). Uslng the equlty method, the carrylng amount of an Investment In an assoclate Is subsequently adjusted through the SOFA to reflect the Investlng charlty's share of the assoclate's results. The carrylng amount thereby reflects the Investor's share of the post acqulsltlon change In the net assets of the assoclate. U) Stoek Stock prlnclpally conslsts of artwork donated by artlsts and Is valued at the lower of cost and net reallsable value. Artworks provlded by art15ts are recognlsed In the flnancl81 statements at thelr antlclpated sales prlce. less antlclpated cost of sales 8nd any subsequent Impalrment. (kl Cash and Cash Equlval•nts Cash at bank and In hand includes deposlts whlch can be wlthdrawn wlthln 24 hours wlthout penalty and short-term deposlts which have a maturty period of 4 months or less and are not subject to slgnlflcant rlsk of changes In value. (l) Tax Status Gynaecology Cancer Research Fund (Llmlted by Guarantee) Is a reglstered company, number 04370087 and Is exempt from corporatlon tsx under the provlslons of Sectlons 466-493 of the Corporation Taxes Act 2010. 38
Gynaecology Cancer Research Fd Annual Rewt Incorporaong a Dlrectors. Report and AcCnts for the year endlng 31 December 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 (m) Op•ratlng Lea5 Rentals payable under operatlng leases are charged to the Statement of Flnanclal Actlvftles as Incurred over the period of the lease on a stralght-llne basls. (n) P•n•lon• The Charlty operates a deflned contrlbutlon penslon scheme. The contrlbutlons to the deflned contrlbutlon scheme are charged to the Ststement of Flnanclal Actlvltles as they become payable. (•) Flnan¢lal Instrum•nts The Charlty only has financlal assets and flnancl81118bllltles of a klnd that quallfy as baslc flnanclal Instruments. Baslc flnanclal Instruments are Initlally recognlsed at transactlon value and subsequently measured at thelr settlement value. The Charlty does not have any bank loans, (p) Slgnllkant Accountlng Estlmat•s and Judg•m•nts EstSmates and Judgements are contlnually evaluated and are based on hlstorlcal experlence and other factors. Includlng expectatlons of future events that are belleved to be reasonable under the clrcumstances: (l) Glft• In klnd Glfts In klnds are recognlsed wlthln Incomlng resources and expendlture at an estlmate of the value to the Charlty of the donated servlces or goods. Where posslble the value of seNlceslgoods are conflrmed dlrectty wlth the suppller however In some Instances thls Informatlon Is not avallable and a best estlm8ted Is made of the expected cost of such goods based on whet the Charlty would be wllllng to pay for slmllar servlces or goods at a market rate. 39
Gynaecology Cancer Research Fund Annual Report Incorporallng a Olrectors. Report and Accourts for the year erKllng 31 December 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 3. Ine¢)me: donatlon• and legacles 2024 Unrestrlcted Restrlcted 2023 Total Indlvldual glvlng Communlty Trust and foundatlons Major donors Corporate Legacles Glfts In klnd Totsl 335,650 376,039 48,632 20,524 230,527 28,866 190,772 1231010 14,494 26,462 274,370 66,250 6,000 40,000 350,144 402,501 323,002 86,774 236,527 68,866 190,772 427 576 1658 586 328.189 358.871 237.700 37,671 108,278 55.870 114 626 1241205 In 2024 £1,141,788 (2023: £880.855) of donatlon and legacles related to unrestrlcted funds and £427.576 (2023: £325,956) was attrlbut8ble to restrlcted funds. Income from donatlon and legacles Include donated serylces worth £190.77212023: £114.626) 4. Incom•: from tradlng actlvltl•s 2024 Unrestrlcted Restrlcted Total 2023 Communlty Tradlng subsldlary (see note 16) Totsl 101550 101550 101550 101550 40
Gynaecology Cancer Researth Fund Annual Report Inconxyatlng a Dlrectors. Report and Accounts for the year endlng 31 December 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 5. Ana19 of •xpondltur• Dlrect costs Support Governance costs cost Total 2024 Expendtture on ralslng funds (Notes 6,8.9} Expenditure on charitable activities {Notes 458.128 96.970 29.360 584,458 7,8,9) Charlty expendlture on ralslng funds Consolldated 960 614 105 299 31882 1097 795 1418 742 202 269 1418 742 202 269 61242 1682 253 61242 1682 253 Dlrect costs Support Governance costs cost Total 2023 Expendtture on ralslng funds (Note 6,8.9) Expendlture on charltable actlvltles (Note 7,8,9) Charlty expendlture on ralslng funds Consolldated 495.588 80,336 18,832 594,756 850 381 126 894 28 249 1005 524 1345 969 207 230 1345 969 207 230 47 081 1600 280 47 081 1600 280 Expendlture relatlng to ralslng funds In 2024 was £584,374 unrestrlcted (2023: £594,oon and £84 restrlcted (2023: £751). Expendlture on charltable actlvltles In 2024 was £662,812 unrestrlcted (2023: £667,337) Includlng donated serylces worth £190.772 (2023: £114,626) and £434,984 from restrlcted (2023: £338.187). Dlrect cost of generallng donatlons and legacles 2024 Restricted 2023 Unrestrlcted Total Indfvldual glvlng Communlty Trust and foundatlons Major donors Corporate Legacles Central Total 46,842 89,473 469 4.152 12,937 75 46,918 89.482 469 4,152 12,937 48.183 73,112 3,264 727 381 16,152 304,170 353,769 458.128 495 588 304 170 458.044 41
Annual Report Incorpornllng a Dlrectors. Report and Accounts for the year endlng 31 December 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 7. Dlr•ct costs of charltabl• actlvltle• 2024 Unrestrlcted Restrlcted 2023 Total Research grants (note 10) Ask Eve - Nurse-led Informatlon servlce Every Women Promlse- DHSC Informatlon and awareness Outreach Research Glfts In klnd Total 27.071 207,131 234,202 248,861 18,426 11,822 225,838 57,344 75,770 142.876 154,698 225,838 17,262 62,073 76,776 182,275 232,151 17,262 62.073 190 772 48,969 424 612 960 614 850 381 8, Dlr•ct c•sts of gov•rnanc• 2024 Unrestrlcted Restrlcted 2023 Total Group - audlt fees Group - non audlt fees Dlrectors Indemnlty Insurance Insurance Trustee costs Staff and contractor costs Other costs Total 17,256 6,832 2,869 17,256 6,832 2,869 16.679 1,157 1,356 72 27.738 79 77 33.785 423 33,785 423 g. AnatyS of support co•ts 2024 Unrestrlcted Restrlcted 2023 Total Rent. servlce charges and utllltles Insurance IT. phone, and Internet Stsff and contractor costs General corporate senilces Total 13.445 423 27.665 106,695 43,670 191898 2.239 15,684 423 34,286 106,695 13,644 306 35,245 139,282 18,753 207 230 6,621 10,371 202,269 42
Gynaecology Cancer Research Fund Annual Report In¢n0 a Dlrectors, Report and Accounts for the year endlng 31 December 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 10. R•••arch grants award•d by In•lltutl¢)n In¢lud•d In Charltabh Artlvltl wer• the followlng r•war¢h grant&" 2024 Restrlcted 2023 Unrestrlcted Total Unfverslty College London University of Birmingham AMRC Fellowshlp Ovarlan Cancer Rare Gynae BGCS Audlt Grant commltments reclalmed Total 22.250 17.750 40.000 167,026 89,700 44,249 56,126 89,006 44,249 56.126 90,948 5,000 1,942 5,000 207 131 234 202 248 861 11. Staff costs 2024 2023 Wages and salarles Soclal securlty Costs Staff penslon 718,591 70,230 722.297 69,819 820,518 819.769 Costs of contracts Total staff costs 865 455 891268 Total number of employees whose total employee benefits (excludlng employer penslon costs and employer natlonal Insurance contrlbutlons) amounted to over £60,000 In the year were: 2024 2023 £70.000 - £79,999 £80,000 - £89,999 £90,000 - £99.999 Average staff numbers: Charftable actfvltles Fundralslng and support 10 11 18 20 43
Gynaecology Cancer Research Fund Annual Report Incorpor8tlNJ a Dlrectors. Report and Accounts for the yew endlng 31 Dernber 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 The key management personnel of the parent charlty comprlses the Chlef Executlve, the Dlrector of Fundralslng, the Head of Programmes and the Head of Finance. The total employee beneflt of the key management personnel In the year were £309,683 (2023: £277.417). 12. Trust•M r•mun•ratlon and •xp•ns•s ol b•n•fft• In klnd None of the trustees recelved any remuneratlon durlng the year (2023: None). Durlng the year £2,869 {2023: £1,157) was pald In respect of trustees, Indemnlty Insurance. No trustees clalmed for any expenses durlng the year (2023: none). 13. N•t mov•m•nt In funds 2024 2023 Net movement In funds Is Stated after charglng: Audftors remuneratlon - current year Amortlsatlon Depreclatlon Amounts payable under operatlng leases: 17,256 799 8,662 15.579 799 8,011 Land and bulldlngs 38,433 46.747 44
Gynaecology Cancer Research Fund Annual Report Incorporatlng a Dlrectors. Report and Attounts for the yew endlng 31 December 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 14. Intanglble flxed assets- Group and Charlty Trademarks Cost at 1° January 2024 7.988 Amortlsatlon: At 1" January 2024 Charge for the year At 31$1 December 2024 4,527 799 5,326 Net book value at 31" December 2024 Net book value at December 2023 15. Tanglbl• flx•d aM•ts Flttlng & Equlpment Cost: At 1st January 2024 Addltlons Dlsposal At 31st December 2024 113,038 1.288 33.450 Depreclatlon: At 1" January 2024 Charge for the year Depreclation on dlsposals At 31" December 2024 95,057 8,662 22,843 Net book value at 3V December 2024 Net book value at 3fl December 2023 45
Gynaecola9y Cancer Research Fund Annual Report Incorporallng a Dlreclws, Report arKI Accowbts ft•r the year endlng 31 December 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 16. Inve•tments held as Ilxed assets - ¢harlty 2024 2023 Shares In subsidlary undertaklng at cost Shares In Jolnt Venture at falr value 7,432 Jolnt Venture The charlty has a share In Sola Dlagnostlcs GmBh, an Austrlan company. Shares (whlch wlll decrease over tlme) were glfted to the Charlty from Professor Martln Wldschwendter. The carrying amount of the Investment was £7.4318t the year end. whlch Is deemed to be Its falr value. Subsldlary The ch8rSty has wholly owned subsldlary Incorporated In England. Eve Appeal Llmlted, whlch ralses funds through activity Includlng cause related marketlng and sales of goods. The company pays its proflt under Glft Ald to the Gyn8ecologlcal Cancer Research Fund. A summary of Its tradlng results (Included wlth 'Other tradlng actlvftles.) for the perlod ended 31 December 2024 Is as follows: 2024 2023 Proflt and loss Turnover Admlnlstratlon expenses Net proflt before tax Taxatlon Net result Proflt and loss reserves Brought forward at 1st January Net result In perlod Dlstrlbutlon to Gynaecology Cancer Research Fund 101,550 2,940 104,490 87,901 85,631 104 490 85.631 104,490 26,653 85.631 104.490 Summary Balance Sheet Current assets Debtors Cash at bank and In hand Total current assets 74,845 30.715 105.560 28,339 115.759 Current Ilabllftles Creditors- amounts falllng due wlthln one year Net current assets Total assets less totsl Ilabllftles 1,069 104,491 104 491 30,129 85.630 Capltal and reserves Share capltal Profft and loss accounts Total 104.490 104 491 85.632 46
Annual Report IncorporallNJ 8 Dlrectors. Report and ACcots for the year endlng 31 December 2024 Notes to the Flnanclal Statements For the Year End 31 DeceMr 2024 Group Charlty 2024 2023 2024 2023 Trade debtors 65.696 34,239 22,337 5.896 Amount owed by group undertaklngs Prepayment and accrued Income Other debtors 18.181 133.053 2.472 201,221 146,163 133,053 2.471 157 861 146.163 191.025 180 863 18. Cr•dltor• Group Charlty 2024 2023 2024 2023 Grants payable Trade credltors Amount owed to group undertaklngs Accruals Taxatlon and soclal securlty Other credltors 447,286 16,363 418,838 15,631 447,286 9,625 38,223 24,820 418,838 9,021 25,888 20,450 15.250 1,251 160 1.250 20 499 679 530 095 19. Unvestrlcted funds- Group At1 January 2024 Income Expendlture At31 December 2024 General funds Emergency fund 182.326 180,000 362 326 1355 262 1.355,262 {1.247.186) 290,402 180 000 470 402 1,247,186 Emergency fund The reseNes pollcy for the charlty, as agreed by the Trustees, Is to malntsin a mlnlmum of three months budgeted expendlture, excludlng expenditure on research grants. Further Information on thls and the ratlonale for thls can be found In the reserves sectlon of the Trustees Report. 47
Gynaecology Cancer Research Fund Annual Report Incorporatlng a Dlrectors. Report and Accounts for the year endlng 31 December 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 Unrnstrkted funds . Charlty At1 January 2024 Income Expendlture At31 December 2024 General funds Emergency fund 96,697 180 000 276 697 1,339,342 (1,250,127) 185,912 180.000 365 912 1339 342 20. Rtrkt•d Fund•- Group At1 January 2024 Income Expendlture At31 December 2024 Ask Eve BRCA Research Vulval Cancer Awareness HPV Resources Rare Gynaecology Research Ovarlan Cancer Research UCL Strateglc Research Fundlng Every Women Promlse Outreach Fellowshlp 109,497 50 1.445 1,317 (57,427) (1) 52.070 16,044 1,445 79,410 678 15,995 78,093 678 66,167 60,245 12,750 66,886 18.587 60 319 461 427 576 22.840 99.057 6,000 143,121 (89,006) (56,126) (17,750) (153,247) (17,262) 44,249 435 068 103,176 1,000 56,760 1.325 60 311969 Restrlcted Funds: Ask Eve: The nurse let Informatlon servlce provldlng free, confldentlal, gynae Informatlon vla phone or emall. BRCA Research: Several of our research programmes have a strong focus on the BRCA gene mutatlon to early detect or prevent ovarlan and breast cancer - for example BRAC Project, BRCA UNITE and GCaPPS. Vulval Canc•r. Vufval cancer Is one of the rare gynaecologleal cancers wlth Just over 1,000 cases In the UK dlagnosed each year. Increased awareness of the signs and symptoms of vulval cancer are essential to ensure that women see thelr GP as soon as they notlce somethlng not rlght for them and to keep going back rf it continues.
Gynaecology Cancer Resewch Fund Annual Rep Incwratlng a Dlrectors. Report and Accounts for the year endlng 31 December 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 Awaren. Thls fund Is restrlcted to ralsing awareness of gynaecologlcal cancers and communlcatlon work around certaln campalgns such as Gynae Cancer Awareness Month. HPV R•4ourcw' Thls project works to embed a deeper and more nuanced publlc understandlng of HPV. seelng to reduce dlsease rlsk, promote preventatlve behavioural change, and Improve patlent outcomes for HPV and related dlsease across the board. Rar• Gynaecologlcal Cancer Remarch: Less than 5% of the 21,000 women dlagnosed wlth gynaecologlcal cancer In the UK are dlagnosed wlth the rate form. The low number of new cases of these rare cancers mean Indlvldual doctors are unfamlllar wlth symptoms, too often resultlng In a late dlagnosls, wlth treatment that may not be optlmal for the dlsease type and subsequent progresslon of the dlsease. More research to advance and Improve the early dlagnosls and preventlon rare 9ynaecologlcal cancers. Ovarlan Can¢•r Rew4rch: In the UK nearty 7,500 people are dlagnosed wlth ovarian cancer every year. The symptoms are not always obvlous. and It Is often dlagnosed In a late state, Research Into early detectlon, rlsk predlctlon and preventlon Is needed. UCL Str•t•gk R•m)h Fundlng: Focuslng on Prof. Wldschwendter's research contlnulng at UCL. The Cllnlcal Assessment & work up of the WIDqEC test In women at hlght rlsk for Endometrl81 (Womb) Cancer. Every Women Prom1. Thls project supports and educates women In the workplace, to report symptoms and seeks advlce on gynaecologlcal health Issues and makes employers aware of the Issues. The alm Is to both Improve the health chances for each woman but to Improve to corporate envlronment, through engagement at a corporate ownershlp and management level. Outreach: Thls project addressed the dlsparltles In gynaecologlcal health outcomes among Black women by Improvlng awareness, access to Informatlon. and confldence In seeklng medlcal care for gynae cancers and overall health. Thls fundlng enabled us to dellver tallored educatlon, develop new partnershlps. and create sustalnable resources that wlll beneflt communltles beyond the Inltlal grant perlod. Folloh1 We appolnted our first Inaugural fellow: Dr Kelechl Njoku from the Unlverslty of Manchester, who Is using hls fellowship to develop a slmpler and klnder test for detecting womb cancer. We received a large grant from the AMRC towards thls programme. 49
Gynaecology Carbcer ReSr¢h Fund Annual Report Inc¢)rporallng a Dlrectors. Report and A£counts for the year endlng 31 December 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 21. Anatysls of N•t Asmts b•tw••n Funds. Group 2024 Restrfcted 2023 Unrestrlcted Totsl Flxed Assets Current Assets Credltors: amounts falllng due withln 1 year Total 20,700 949,381 20.700 311.969 1.261.350 28.873 1,119,920 499 679 470 402 499.679 782 371 311,969 681.787 22. L¢g81 Status •fth• CrIty The charity is limited by guarantee and therefore does not have share capltal. The Ilablllty of the members15 Ilmlted to the sum of £1 per member, and the number of members was 13 (2023: 13). 23. Uftlmat• Controlllng P•rty Eve Appeal Llmlted Is a wholly owned subsldlary of Gynaecology Cancer Research Fund, whlch Is the ultlmate controlllng party, The uttlmate controlllng paty of Gynaecology Cancer Research Fund are the Trustees, 24. R•lated Party Tran•artlon• Durlng the year under revlew, the charlty recelved Income totalllng £18,070 In donatlons from 9 Trustees, both current and reslgned In the perSod, Includlng partners (2023: £20,254 from 7 Trustees Includlng partners). Reed Smlth LLP provlded pro bono legal servlces and other support to the charlty totalllng £80.116 (2023: 14,989). Tamara Box, a partner at Reed Smlth LLP Is also chalr of board of trustee of the charlty. 25. Commltm•nts under operatlng leas The group and charlty had the followlng future mlnlmum lease payment under non-cancellable operatlng leases: Group Charlty 2024 2023 2024 2023 Land and bulldlng&" Wlthln one year Between one year and flve years 10,675 25,357 10,657 10.675 25.357 10,675 36,090 qulpment: Wlthln one year Between one year and flve years £840 £1,561 £840 Total Commltments £46 747 £38 433 50